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INTRODUCTION 
The 6th International Consultation on Incontinence met between September 13-15th 2016 in Tokyo and was 
organised by the International Consultation on Urological Diseases and the International Continence Society 
(ICS), in order to develop consensus statements and recommendations for the diagnosis, evaluation and treat-
ment of urinary incontinence, faecal incontinence, pelvic organ prolapse and bladder pain syndrome.  
The consensus statements are evidence based following a thorough review of the available literature and the 
global subjective opinion of recognised experts serving on focused committees. The individual committee re-
ports were developed and peer reviewed by open presentation and comment. The Scientific Committee, con-
sisting of the Chairs of all the committees then refined the final consensus statements.These consensus state-
ments published in 2017 will be periodically reevaluated in the light of clinical experience, technological pro-
gress and research. 
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1. DEFINITIONS 
The consultation agreed to use the current Interna-
tional Continence Society definitions (ICS) for lower 
urinary tract dysfunction (LUTD) including inconti-
nence, except where stated. These definitions were 
published in the journal Neurourology and Urodynam-
ics (2002; 21:167-178  and  2006; 25: and can be   
viewed on the ICS website: www.ics.org 
The following ICS definitions are relevant: 
1. LOWER URINARY TRACT 
SYMPTOMS (LUTS) 
LUTS are divided into storage and voiding symptoms. 
Urinary incontinence is a storage symptom and de-
fined as the complaint of any involuntary loss of urine. 
This definition is suitable for epidemiological studies, 
but when the prevalence of bothersome incontinence 
is sought, the previous ICS definition of an “Involun-
tary loss of urine that is a social or hygienic problem“, 
can be useful. 
Urinary incontinence may be further defined accord-
ing to the patient’s symptoms 
• Urgency Urinary Incontinence is the complaint 
of involuntary leakage accompanied by or imme-
diately preceded by urgency. 
• Stress Urinary Incontinence is the complaint of 
involuntary leakage on effort or exertion, or on 
sneezing or coughing. 
• Mixed Urinary Incontinence is the complaint of 
involuntary leakage associated with urgency, 
and also with effort, exertion, sneezing and 
coughing. 
• Nocturnal Enuresis is any involuntary loss of 
urine occurring during sleep. 
• Post-micturition dribble and continuous uri-
nary leakage denotes other symptomatic forms 
of incontinence. 
Overactive bladder is characterised by the storage 
symptoms of urgency with or without urgency in-con-
tinence, usually with frequency and nocturia. 
2. URODYNAMIC DIAGNOSIS 
• Detrusor Overactivity is a urodynamic observa-
tion characterised by involuntary detrusor con-
tractions during the filling phase, which may be 
spontaneous or provoked. 
Detrusor overactivity is divided into: 
o Idiopathic Detrusor Overactivity, defined 
as overactivity when there is no clear cause 
o Neurogenic Detrusor Overactivity is de-
fined as overactivity due to a relevant neu-
rological condition. 
• Urodynamic stress incontinence is noted dur-
ing filling cystometry, and is defined as the invol-
untary leakage of urine during increased ab-
dominal pressure, in the absence of a detrusor 
contraction. 
3. BLADDER PAIN SYNDROME 
Bladder pain syndrome is defined by ESSIC as 
chronic pelvic pain, pressure or discomfort of greater 
than 6 months duration perceived to be related to the 
urinary bladder accompanied by at least one other 
urinary symptom like persistent desire to void or uri-
nary frequency.  Confusable diseases as the cause 
of the symptoms must be excluded. 
4. PELVIC ORGAN PROLAPSE 
• Urogenital prolapse is defined as the sympto-
matic descent of one or more of: the anterior vag-
inal wall, the posterior vaginal wall, and the apex 
of the vagina (cervix/uterus) or vault (cuff) after 
hysterectomy. Urogenital prolapse is measured 
using the POP-Q system. 
• Rectal prolapse is defined as circumferential full 
thickness rectal protrusion beyond the anal mar-
gin. 
5. ANAL INCONTINENCE 
Anal incontinence defined as “any involuntary loss 
of faecal material and/or flatus and/or mucus” and 
may be divided into: 
• Faecal incontinence, any involuntary loss of 
faecal material 
• Flatus incontinence, any involuntary loss of gas 
(flatus) 
• Mucus incontinence, any involuntary loss of 
mucus only (not faeces) 
* At the time of this consultation, these definitions are 
not included in the current ICS terminology. 
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2. EVALUATION 
The following phrases are used to classify diagnos- 
tic tests and studies: 
• A highly recommended test is a test that should 
be done on every patient. 
• A recommended test is a test of proven value 
in the evaluation of most patients and its use is 
strongly encouraged during evaluation. 
• An optional test is a test of proven value in the 
evaluation of selected patients; its use is left to 
the clinical judgement of the physician 
• A not recommended test is a test of no proven 
value. 
This section primarily discusses the Evaluation of Uri-
nary Incontinence with or without Pelvic Organ Pro-
lapse (POP) and Faecal Incontinence. 
The recommendations are intended to apply to chil-
dren and adults, including healthy persons over the 
age of 65. 
These conditions are highly prevalent but often not 
reported by patients. Therefore, the Consultation 
strongly recommends case finding, particularly in 
high risk groups. 
A. HIGHLY RECOMMENDED 
TESTS DURING INITIAL 
EVALUATION 
The main recommendations for this consultation 
have been abstracted from the extensive work of the 
23 committees of the 6th International Consultation 
on Incontinence (ICI, 2016). 
Each committee has written a report that reviews and 
evaluates the published scientific work in each field of 
interest in order to give Evidence Based recommen-
dations. Each report ends with detailed recommenda-
tions and suggestions for a programme of research. 
The main recommendations should be read in con-
junction with the management algorithms for children, 
men, women, the frail older person, neurogenic pa-
tients, bladder pain, pelvic organ prolapse, and anal 
incontinence 
The initial evaluation should be undertaken, by a cli-
nician, in patients presenting with symptoms/ signs 
suggestive of these conditions. 
1. HISTORY AND GENERAL 
ASSESSMENT 
Management of a disease such as incontinence re-
quires caregivers to assess the sufferer in a holis- tic 
manner. Many factors may influence a particular indi-
vidual’s symptoms, some may cause incontinence, 
and may influence the choice and the success of 
treatment. The following components of the medical 
history are particularly emphasised: 
1.1. Review of Systems: 
• Presence, severity, duration and bother of any 
urinary, bowel or prolapse symptoms. Identifying 
symptoms in the related organ systems is critical 
to effective treatment planning. The use of vali-
dated questionnaires to assess symptoms are 
recommended. 
• Effect of any symptoms on sexual function: vali-
dated questionnaires including impact on quality 
of life are a useful part of a full assessment. 
• Presence and severity of symptoms suggesting 
neurological disease 
1.2. Past Medical History: 
• Previous conservative, medical and surgical 
treatment, in particular, as they affect the genito-
urinary tract and lower bowel. The effectiveness 
and side effects of treatments should be noted. 
• Coexisting diseases may have a profound effect 
on incontinence and prolapse sufferers, for ex-
ample asthma patients with stress incontinence 
will suffer greatly during attacks. Diseases may 
also precipitate incontinence, particularly in frail 
older persons. 
• Patient medication: it is always important to re-
view every patient’s medication and to make an 
assessment as to whether current treatment may 
be contributing to the patient’s condition. 
• Obstetric and menstrual history. 
• Physical impairment: individuals who have com-
promised mobility, dexterity, or visual acuity may 
need to be managed differently 
1.3. Social History: 
• Environmental issues: these may include the so-
cial, cultural and physical environment. 
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• Lifestyle: including exercise, smoking and the 
amount and type of fluid and food intake. 
1.4. Other Treatment Planning Issues: 
• Desire for treatment and the extent of treatment 
that is acceptable 
• Patient goals and expectations of treatment 
• Patient support systems (including caregivers). 
• Cognitive function: all individuals need to be 
assessed for their ability to fully describe their 
symptoms, symptom bother and quality of life im-
pact, and their preferences and goals for care. 
They must be able to understand proposed man-
agement plans and to discuss, where appropri-
ate, alternative treatment options. In some groups 
of patients, formal testing is essential e.g. cogni-
tive function testing for individuals for whom the 
clinician has concerns regarding memory deficits 
and/or inattention or confusion, and depression 
screening for individuals for whom the clinician 
has concerns about abnormal affect. Proxy re-
spondents, such as family and caregivers, may 
be used to discuss the patient’s history, goals of 
care, and treatment for individuals with dementia, 
but only if the individual is incapable of accurate 
reporting or weighing treatment decisions. 
2. PHYSICAL EXAMINATION 
The more complicated the history and the more ex-
tensive and/or invasive the proposed therapy, the 
more complete the examination needs to be. De-
pending on the patient’s symptoms and their severity, 
there are a number of components in the examination 
of patients with incontinence and/or pelvic organ pro-
lapse. 
Physical examination should be performed regard- 
less of whether the patient is a child, a woman, a man, 
someone with neurological disease or a frail elderly 
person. 
2.1. General status: 
• Mental status 
• Obesity (BMI) 
• Physical dexterity and mobility 
2.2. Abdominal/flank examination: for 
masses, bladder distention, relevant sur- 
gical scars 
2.3. Pelvic examination: 
• Examination of the perineum and external geni-
talia including tissue quality and sensation. 
• Vaginal (half-speculum/Sims) examination for 
pelvic organ prolapse (POP), which should be 
done in the vertical position 
• Bimanual pelvic and anorectal examination for 
pelvic mass,  
• Digital rectal examination to assess pelvic floor 
muscle function and the function of internal and 
external anal sphincter as well as puborectalis 
muscle. 
• Stress test for urinary incontinence. 
2.4. Neurological testing (see chapter on 
assessment) 
3. URINALYSIS 
In patients with LUTS, the possibility of a urinary tract 
infection should be evaluated, with appropriate test-
ing (ranging from dipstick to urine microscopy and 
culture when indicated as UTI is a readily detected, 
and easily treatable cause of LUTS, 
Conclusion 
For simple treatments, particularly non- invasive and 
inexpensive therapies, management may start with-
out the need for the further investigations listed be-
low. 
B. RECOMMENDED FURTHER 
ASSESSMENT PRIOR TO, OR 
DURING, SPECIALIST 
ASSESSMENT 
The tests below are recommended when the appro-
priate indication(s) is present. Some recom- 
mended tests become highly recommended in spe-
cific situations. 
This section should also be read in conjunction with 
the relevant committee reports. 
1. FURTHER SYMPTOM AND 
HEALTH-RELATED QOL 
ASSESSMENT 
1.1. Bladder Diary 
In patients with urinary symptoms the use of a blad-
der diary (examples in Annex 1) is highly recom-
mended to document the frequency of micturition, the 
volumes of urine voided, incontinence episodes and 
the use of incontinence pads. 
1.2. Questionnaires 
The use of the highest quality questionnaires (GoR 
A, where available) is recommended for the assess-
ment of the patient’s perspective of symptoms of in-
continence and their impact on quality of life. 
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The ICIQ is highly recommended (GoR A) for the 
basic evaluation of the patient’s perspective of urinary 
incontinence, with other GoR A questionnaires rec-
ommended for more detailed assessment. Further 
development is required in the areas of pelvic or-
gan prolapse, bladder pain syndrome, and for specific 
patient groups, as only GoR B questionnaires are cur-
rently available (see Assessment Chapter). 
2. RENAL FUNCTION ASSESSMENT 
Standard biochemical tests for renal function are rec-
ommended in patients with urinary incontinence 
when there is the possibility of renal impairment. 
3. UROFLOWMETRY 
Uroflowmetry with the measurement of post void re-
sidual urine is recommended as a screening test for 
symptoms suggestive of urinary voiding dysfunction 
or physical signs of POP or bladder distension. 
Uroflowmetry should be part of the initial assessment 
if the result is likely to influence management eg in 
older men with possible prostatic obstruction. 
4. ESTIMATION OF POST VOID 
RESIDUAL URINE (PVR) 
In patients with suspected voiding dysfunction, PVR 
should be part of the initial assessment if the result is 
likely to influence management, for example, in neu-
rological patients. 
5. IMAGING 
Although routine imaging is not recommended, imag-
ing of the lower urinary tract and pelvis is highly rec-
ommended in those with urinary symptoms whose in-
itial evaluation indicates a possible co- existing lower 
tract or pelvic pathology. Initial imaging may be by ul-
trasound, or plain X-ray. 
Imaging of the upper urinary tract is highly recom- 
mended in specific situations. These include: 
• Haematuria, 
• Neurogenic urinary incontinence e.g. myelodys- 
plasia, spinal cord trauma, 
• Incontinence associated with significant post-
void residual, 
• Co-existing renal disease such as pyelonephritis 
or reflux, or loin/kidney pain, 
• Severe pelvic organ prolapse, not being treated 
• Suspected extra-urethral urinary incontinence, 
• Children with incontinence and UTIs, where indi-
cated 
• Urodynamic studies which show evidence of 
poor bladder compliance or high pressure detru-
sor overactivity. 
6. INVESTIGATIONS IN FAECAL 
INCONTINENCE AND RECTAL 
PROLAPSE 
• Endoanal US or MRI prior to anal sphincter sur-
gery is highly recommended, even when obvious 
anatomic defects are not evident.  
• Defaecating proctography or dynamic MRI is rec-
ommended in suspected rectal prolapse which 
cannot be adequately confirmed by physical ex-
amination.  
• Anorectal manometry is useful to assess resting 
and squeeze anal pressures. The resting and 
squeeze pressures represent the function of the 
internal and external anal sphincter, respectively. 
7. ENDOSCOPY 
Although routine cysto-urethroscopy is not recom- 
mended, LUT endoscopy is highly recommended: 
• When initial testing is abnormal, e.g. haematuria 
and suggests other pathologies,  
• When pain or discomfort feature in the patient’s 
LUTS, these may suggest an intravesical lesion 
• When appropriate in the evaluation of vesicovag-
inal fistula and extra-urethral urinary inconti-
nence (in childbirth fistulae, endoscopy is often 
unnecessary). 
In anorectal conditions, proctoscopy or flexible sig-
moidoscopy should routinely be performed in the 
evaluation of patients with faecal incontinence. Co-
lonoscopy, air contrast barium enema or CT colog-
raphy is highly recommended in the presence of un-
explained change in bowel habit, rectal bleeding or 
other alarm symptoms or signs (see Basic Assess-
ment chapter). 
8. URODYNAMIC TESTING 
8.1. Urodynamic (multi channel pressure 
subtracted cystometry) evaluation is 
recommended 
• When the results may change management, 
such as prior to most invasive treatments for UI 
and POP, 
• After treatment failure, if more information is 
needed in order to plan further therapy, 
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• As part of both initial and long-term surveillance 
programmes in some types of neurogenic lower 
urinary tract dysfunction, 
• In “complicated incontinence” (for details please 
see relevant subcommittee reports). 
8.2. The aims of urodynamic evaluation are 
often diagnostic, but may also relate to 
prognostic factors, direct management 
or assess response to prior therapy, 
and also: 
• To reproduce the patient’s symptoms and corre-
late these with urodynamic findings 
• To assess bladder sensation 
• To detect detrusor overactivity 
• To assess urethral competence during filling 
• To determine detrusor function during voiding 
• To assess outlet function during voiding 
• To assess residual urine 
9. SMALL BOWEL FOLLOW-
THROUGH, CT ENTOGRAPHY OR 
CAPSULE ENDOSCOPY 
These tests are recommended in those with faecal in-
continence and the presence of unexplained diar-
rhoea or when Crohn’s disease is suspected. 
C. FURTHER DIAGNOSTIC TESTS 
TO BE USED AS APPROPRIATE 
1. ADDITIONAL URODYNAMIC 
TESTING 
Video-urodynamics may be useful in the manage-
ment of UI in children, in patients who fail surgery and 
in some neurogenic patients, to obtain additional an-
atomical information. Either X-ray or US imaging can 
be used depending on the needs of the individual pa-
tient. 
If a more detailed estimate of urethral function is 
required, then the following optional tests may give 
useful information: 
• Urethral pressure profilometry 
• Abdominal leak point pressures 
• Video-urodynamics 
• Electromyography of pelvic floor or urethral 
sphincter 
If initial urodynamics have failed to demonstrate 
the cause for the patient’s incontinence then the fol-
lowing tests are optional: 
• Repeated routine urodynamics or video-urody-
namics 
• Ambulatory urodynamics 
2. PAD TESTING 
Pad testing is an optional test for the routine evalua-
tion of urinary incontinence and, if carried out, a 24 hr 
test is suggested. 
3. NEUROPHYSIOLOGICAL TESTING 
AND IMAGING 
The information gained by clinical examination and 
urodynamic testing may be enhanced by neuro- 
physiological testing of striated muscle and nerv-
ous pathways. 
Appropriately trained personnel should perform these 
tests. The following neuro-physiological tests can be 
considered in patients with peripheral lesions prior to 
treatment for lower urinary tract or anorectal dysfunc-
tion. 
• Concentric needle EMG 
• Sacral reflex responses to electrical stimulation 
of penile or clitoral nerves. 
Imaging of the nervous system (and neighbouring 
structures, including spine, the abdominal cavity and 
pelvis) by MRI or CT, may confirm suspected involve-
ment of the nervous system, and the nature of the 
cause. 
4. FURTHER IMAGING 
Cysto-urethrography, US, CT and MRI may have an 
indication: 
• Suspected pelvic floor dysfunction 
• Failed surgery, such as recurrent posterior vagi-
nal wall prolapse or failed sling surgery 
• Suspected fixed urethra 
5. CYSTO-URETHROSCOPY 
This is an optional test in patients with complicated, 
persistent or recurrent UI (e.g. after failed SUI sur-
gery) 
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6. ANORECTAL PHYSIOLOGY 
TESTING 
Endocoil MRI has high accuracy for detecting anal 
sphincter injury but is second line after endoanal ul-
trasound. Patients with faecal incontinence may ben-
efit from assessment with MRI, particularly those with 
anorectal malformations and/or previous anal sphinc-
ter surgery. 
Defaecography may be useful and is recommended 
in patients with faecal incontinence, who have failed 
conservative therapies, and are possible candidates 
for laparoscopic ventral rectopexy. 
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3. MANAGEMENT CONSENSUS 
STATEMENTS 
The consensus statements are derived from the de-
tailed work in the committee reports on the man-
agement of incontinence in children, men, women, 
the frail elderly and neurological patients, as well as 
those with obstetric fistula, pelvic organ prolapse, 
bladder pain syndrome, and faecal incontinence. The 
management of incontinence is presented in algo-
rithm form with accompanying notes. 
The chapters analyze the evidence and give it a level 
of evidence (LoE) and this generates a GoR of rec-
ommendation (GoR) 
The Consultation recognises that no algorithm 
can be applied to every patient and each patient’s 
management must be individualised. 
There are algorithms for 
I. Urinary Incontinence in Children 
II. Urinary Incontinence in Men 
III. Urinary Incontinence in Women 
IV. Fistulae 
V. Pelvic Organ Prolapse 
VI. Urinary Incontinence in Neurological 
Patients 
VII. Bladder Pain Syndrome 
VIII. Faecal Incontinence in Adults  
IX. Urinary and faecal Incontinence in frail 
Older Men and Women 
These algorithms are divided into two for groups I to 
III, VII and X. The two parts, initial management and 
specialised management require a little further ex-
planation. 
Although the management algorithms are designed 
for patients whose predominant problem is inconti-
nence, there are many other patients in whom the al-
gorithms may be useful such as those patients with 
urgency and frequency, so-called “OAB dry 
Management definitions 
Management may be divided into 
• Conservative, all methods that are non-medical 
and non-surgical, some of which do not target the 
disease process 
• Medical (pharmacological) therapy 
• Surgical therapy 
• Conservative therapy includes 
o Lifestyle interventions e.g. weight loss 
o Bladder training 
o Pelvic floor muscle training (PFMT) 
o Containment products e.g. pads 
o Dependent continence strategies eg regular 
toileting 
Consensus does not exist as to the use of the term 
“behavioural therapy” as some state that this term 
only includes bladder training and PFMT, whilst oth-
ers consider that all conservative management con-
tains a behavioural element, for example wearing and 
changing pads constitutes a change in behaviour. 
Hence the consultations recommendations list the el-
ements of conservative management as relevant are 
intended for use by all clinicians including health care 
assistants/aides, nurses, physiotherapists, generalist 
doctors and family doctors as well as by specialists 
such as urologists, geriatricians and gynaecologists. 
The consultation has attempted to phrase the recom-
mendations in the basic algorithms in such a way that 
they may be readily used by clinicians in all countries 
of the world, both in the developing and the devel-
oped world. 
The algorithms for initial management 
are intended for use by all clinicians including health 
care assistants/aides, nurses, physiotherapists, gen-
eralist doctors and family doctors as well as by spe-
cialists such as urologists, geriatricians and gynae-
cologists. The consultation has attempted to phrase 
the recommendations in the basic algorithms in such 
a way that they may be readily used by clinicians in 
all countries of the world, both in the developing and 
the developed world. 
The specialised algorithms 
The specialised algorithems are intended for use by 
specialists. The specialised algorithms, as well as 
the initial management algorithms are based on evi-
dence where possible, and on the expert opinion 
of the 400 healthcare professionals who took part in 
the Consultation. In this consultation, committees as-
cribed levels of evidence to the published work on the 
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subject and devised GoRs of recommendation to in-
form patient management. 
It should be noted that these algorithms, dated April 
2017, represent the Consultation consensus at that 
time. Our knowledge, developing from both a re-
search base and because of evolving expert opinion, 
will inevitably change with time and relate to the 
unique context of individual patients seeking 
care. The Consultation does not wish those using the 
algorithms to believe they are “carved in tablets of 
stone”: there will be changes both in the relatively 
short term and in the long term. 
1. ESSENTIAL COMPONENTS OF 
BASIC ASSESSMENT 
Each algorithm contains a core of recommendations 
in addition to a number of essential components of 
basic assessment listed in sections I to III. 
• General assessment 
• Symptom assessment 
• Assessment of quality of life impact 
• Assessment of the desire for treatment 
• Physical examination 
• Urinalysis 
 
2. JOINT DECISION MAKING 
The patient’s desires and goals for treatment: 
Treatment is a matter for discussion and joint decision 
making between the patient and his or her health care 
advisors. This process of consultation includes the 
specific need to assess whether or not the patient 
wishes to receive treatment and, if so, what treat-
ments he or she would favour. Implicit in this state-
ment is the assumption that the health care provider 
will give an appropriate explanation of the pa-
tient’s problem and the alternative lines of man-
agement, and the potential benefits and risks of 
treatment. The assumption that patients almost al-
ways wish to have treatment is flawed, and the need 
to incorporate patient values and preferences is par-
amount. 
In each algorithm, treatments are listed in order of 
simplicity, the least invasive being listed first. This 
order does not imply a scale of efficacy or cost, two 
factors which need to be considered in choosing the 
sequence of therapy. The order is likewise not meant 
to imply a suggested sequence of therapy, which 
should be determined jointly by the treating health 
care provider and the patient, considering all the rel-
evant factors listed above. 
In the initial management algorithms, treatment is 
empirically based, whilst the specialised manage-
ment algorithms usually rely on precise diagnosis 
from urodynamics and other testing. 
The assumption is made that patients will be reas-
sessed at an appropriate time to evaluate their pro-
gress. 
3. USE OF CONTINENCE PRODUCTS 
The possible role of continence products to pre-
vent, contain and/or manage bladder and/or bowel 
leakage should be considered at each stage of pa-
tient assessment and treatment, to maintain dignity 
and social functioning, and/or to support self-man-
agement or care by others. 
Consider temporary use of continence products:  
• While treatment is awaited. 
• In addition to treatment; for example using pads 
and/or urinals when taking anti-muscarinics or 
carrying out pelvic floor exercises, until sufficient 
improvement is achieved. 
Consider permanent use of continence products: 
• When treatment is not chosen or not suitable for 
the individual 
• When treatment does not achieve (complete) 
cure 
• For intermittent use; for example when the pa-
tient has a cough, or needs to travel without reli-
able toilet access 
• For continuous use if incontinence is unpredict-
able and/or frequent or if complications related to 
incontinence (e.g. skin breakdown) are imminent 
or present 
Consider offering a mixture of continence products 
(disposable/washable; absorbent/non-absorbent) to 
optimise effectiveness and to reduce costs; e.g. dif-
ferent products for day and night; or for staying at 
home and for going out/travel/specific activities. 
Further guidance on management with continence 
products is given in Chapter 20 and at the ICI/ICS 
supported website: 
www.continenceproductadvisor.org 
At the foot of each of the treatment algorithms below, 
the phrase “Consider CONTINENCE PRODUCTS for 
temporary support during treatment”, emphasizes the 
importance of continence products for many sufferers 
of incontinence 
  
I. URINARY INCONTINENCE IN CHILDREN 
A. INITIAL MANAGEMENT 
Children present specific management problems for a variety of reasons: assess-
ment requires help from their parents and caregivers; consent to treatment may be 
problematic; and cooperation in both assessment and treatment may be difficult. 
1. INITIAL ASSESSMENT SHOULD INVOLVE A DETAILED 
INVESTIGATION OF VOIDING AND BOWEL HABITS USING 
BLADDER/BOWEL DIARIES AND STRUCTURED AND 
VALIDATED QUESTIONNAIRES. 
The child’s social environment and general and behavioural development should 
also be formally assessed and recorded. Physical examination should be done to 
detect a palpable bladder, faecal loading and exclude anatomic and neurogenical 
causes. Urine analysis and culture is sufficient to exclude the presence of infection. 
If possible, the child should be observed voiding. 
➢ Referrals for specialist treatment are recommended for children who 
have complicated incontinence associated with: 
• Recurrent and febrile urinary infection 
• Voiding symptoms or evidence of poor bladder emptying 
• Urinary tract anomalies 
• Previous pelvic surgery 
• Neuropathy or neuropathic origin 
• Bowel dysfunction not responsive to treatment 
• Comorbid behavioural (e.g. ADHD and ODD) and emotional disorders. 
➢ Initial treatment is recommended for the remaining patients who have: 
• Nocturnal enuresis without other symptoms (monosymptomatic enuresis). 
• Daytime symptoms of frequency, urgency, voiding postponement, straining, in-
terrupted voiding, urgency incontinence with or without nighttime wetting. 
 
2. TREATMENT  
➢ Initial treatment for mono-symptomatic nocturnal enuresis should include: 
• Parental and child counselling and motivation 
• Review of bladder diary with attention to night-time polyuria  
• Age appropriate education and demystification or explanation 
➢ A choice between either bed wetting alarm (GoR A) or anti-diuretic hormone 
analogues of desmopressin (GoR A). It may be a parental and child choice if 
advantages and disadvantages are well explained. 
➢ Daytime incontinence should be managed holistically including: 
• Counselling, timed voiding, behaviour modification and bowel management 
when necessary (GoR B); 
• Antimuscarinics may be used if the child has OAB symptoms (GoR A)  
  
 
INITIAL MANAGEMENT OF URINARY INCONTINENCE IN CHILDREN 
 
  
HISTORY / 
SYMPTOM 
ASSESSMENT 
CLINICAL 
ASSESSMENT 
TREATMENT* 
PRESUMED 
DIAGNOSIS 
Nocturnal enuresis 
(monosymptomatic) 
Daytime ± Nighttime 
wetting ± Urgency / 
frequency 
General assessment (see relevant chapter) 
• Physical examination: abdominal, perineal, ext. genitalia, back/spine, neurological 
• Assess bowel function -> if constipated, treat and reassess 
• Urinalysis ± Urine culture -> if infected, treat and reassess 
• Assess post-void residual urine by abdominal examination (optional : by ultrasound) 
SPECIALISED MANAGEMENT 
“Complicated” Incontinence associated with: 
• Urinary tract anomaly 
• Neuropathy 
• Pelvic surgery 
• Voiding (emptying) symptoms 
• Recurrent urinary infection 
• Bowel dysfunction not responsive to treatment 
• Comorbid behavioural and emotional disorders 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
• Explanation/education 
• Enuresis Diary 
• Alarm (A) 
• Desmopressin (A) 
Urgency 
Incontinence 
Recurrent Infection Dysfunctional 
Voiding 
Any other 
abnormality 
detected e.g. 
Post void 
residual 
Monosymptomatic 
Nocturnal Enuresis 
• Explanation/education 
• Fluid/voiding regimen (A) 
• Bladder training (B) 
• Antimuscarinics (A) 
• Alarm (bed wetting) (B) 
Failure Failure 
  
I. URINARY INCONTINENCE IN CHILDREN 
B. SPECIALISED MANAGEMENT 
➢ Two groups of children with ‘‘complicated’’ incontinence should have spe- 
cialist management from the outset (Fig. 2). 
• Children whose incontinence is due to, or associated with, urinary tract anom-
alies and neuropathy. 
• Children without urinary tract anomalies, but with recurrent febrile infection 
and, proven or suspected, lower urinary tract dysfunction. 
➢ Children who fail the basic treatment, but who have neither neurogenic nor 
anatomical problems, should also receive specialist management. 
Children with comorbid behavioural and emotional disorders require referral to 
mental health services, as compliance and treatment outcomes are lower. 
Assessment and treatment should follow evidence-based practice guidelines 
1. ASSESSMENT  
➢ As part of further assessment, the measurement of urine flow (in children old 
enough), together with the ultrasound estimate of residual urine and ap-
pearance of the bladder wall and rectum are highly recommended. An evalua-
tion of the upper urinary tracts with ultrasound is also highly recom-
mended. 
Those who do not improve with treatment and have neither neurogenic nor an-
atomical problems should be reassessed using bladder diaries, symptom ques-
tionnaires, urinalysis, uroflowmetry and residual urine determination. 
If there are recurrent and febrile infections, upper tract imaging and possibly 
a VCUG should be considered. However, endoscopy is rarely indicated. 
➢ Urodynamics should be considered: 
• If the type and severity of lower tract dysfunction cannot be explained by 
clinical findings or in the presence of possible relevant neuropathy or urinary 
tract anomalies. (GoR B) 
• If invasive treatment is under consideration, for example, stress incontinence 
surgery if there is sphincteric incompetence, or bladder augmentation if there 
is detrusor overactivity. (GoR B) 
• If upper tract dilation exists and is thought to be due to bladder dysfunction. 
(Gor A) 
• Invasive urodynamic studies are generally not recommended if the child 
has normal upper tract imaging and is to be treated by noninvasive means. 
(Gor B) 
➢ Spinal Imaging (US/X-ray/MRI) may be needed if a bony abnormality or 
neuro-logical condition is suspected. (GoR A) 
2.  TREATMENT          
The treatment of incontinence associated with urinary tract anomalies is complex 
and cannot easily be dealt with in an algorithm. In many children more than one 
pathology demands treatment. If there are complex congenital abnormalities 
present, the treatment is mostly surgical and it should be individualised according 
to the type and severity of the problem (please see Children’s Committee Report). 
Care should be given by specialist children’s nurses and therapists. 
➢ Initial treatment should be non-surgical. 
• For stress urinary incontinence (SUI): pelvic floor muscle training (GoR C). 
• For OAB symptoms: fluid/voiding regimens and antimuscarinics (GoR A). 
• For voiding dysfunction: timed voiding, voiding re-education, pelvic floor 
muscle relaxation (+/- biofeedback), alpha-blocker therapy, and intermittent 
catheterisation (when PVR >30% of bladder capacity) (GoR A/B). 
• For bowel dysfunction: high fibre diet and laxatives as appropriate, and. 
transanal irrigation in severe cases (GoR A). 
  
 
The child’s progress should be assessed and, if quality of life is still significantly 
impaired, or if the upper urinary tracts are at risk, surgical treatment is likely to be 
necessary. 
➢ If surgical treatment is required, then urodynamic studies are recommended 
to confirm the diagnosis. 
• For USI, colposuspension, sling surgery, bulking agent injection and AUS may 
be considered (GoR B). 
• For DO/poor compliance, botulinum toxin (for DO, and off-label) and bladder 
augmentation may be performed (GoR B). 
• If the child cannot do IC then a Mitrofanoff channel may be needed (GoR A). 
  
  
SPECIALISED MANAGEMENT OF URINARY INCONTINENCE IN CHILDREN 
  
EXPERT HISTORY 
& PHYSICAL 
EXAMINATION 
CLINICAL 
ASSESSMENT 
TREATMENT* 
DIAGNOSIS 
Incontinence without 
suspicion of urinary tract 
anomaly 
Incontinence with 
suspicion of urinary tract 
anomaly 
• Urinalysis: if UTI,  treat and reassess (A) 
• Treat bowel dysfunction and reassess (A) 
• Renal / bladder ultrasound (A) 
• Assess post void residual (A) 
• Flow rates ± electromyography (A) 
• Behavioural Evaluation (B) 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
• Pelvic floor muscle training 
(A) 
Detrusor Overactivity / 
Poor Compliance  
UrodynamicStress 
Incontinence 
• Fluid/ voiding regime (A) 
• Antimuscarinics (A) 
• Bowel management 
including transanal irrigation 
(A) 
Failure Failure 
Medicine scan 
Consider: 
• Micturating cystogram (B) 
• Renal nuclear medicine scan (B) 
• if abnormal --> Urodynamics (A) 
• Cystourethroscopy (B) 
• Spinal imaging (A) 
Anatomical Causes of 
Urinary Incontinence 
• Timed voiding (B) 
• Pelvic floor relaxation ± 
biofeedback. (A) 
• Pharmacotherapy 
• Antimuscarinics (B) 
• -blockers (B) 
• Intermittent cath. (B) 
• Bowel management including 
transanal irrigation (A) 
• SNS (B) 
• Correct anomaly (see: 
surgical treatment in 
children) (A) 
• Colposuspension (B) 
• AUS (B) 
• Sling (B) 
• Bulking agent injection (C) 
• Botulinum toxin (B) 
• Bladder augmentation (B) 
• SNS (B) 
• Mitrofanoff if IC fails (A) 
Failure 
Dysfunctional voiding  
  
 
II. URINARY INCONTINENCE IN MEN 
A. INITIAL MANAGEMENT 
1. INITIAL ASSESSEMENT SHOULD IDENTIFY: 
➢ “Complicated” incontinence group  
Those with pain or with haematuria, recurrent infection, suspected or proven poor 
bladder emptying (for example due to bladder outlet obstruction), or incontinence 
following pelvic irradiation or radical surgery, are recommended for specialised 
management. 
Poor bladder emptying may be suspected from symptoms, physical examination 
or if imaging has been performed by X-ray or ultrasound after voiding. 
➢ Four other main groups of men should be identified by initial assessment as 
being suitable for initial management. 
• Those with post-micturition dribble alone, 
• Those with overactive bladder (OAB) symptoms: urgency with or without ur-
gency incontinence, together with frequency and nocturia 
• Those with stress urinary incontinence (most often post-prostatectomy), 
• Those with mixed urinary urgency and stress incontinence (most often post- 
prostatectomy) 
2. MANAGEMENT 
➢ For men with post-micturition dribble, this requires no assessment and can 
usually be treated by teaching the man how to do a strong pelvic floor muscle 
contraction after voiding, or manual compression of the bulbous urethra directly 
after micturition. (GoR B) 
➢ For men with stress, urgency or mixed urgency / stress incontinence, initial 
treatment should include appropriate lifestyle advice, pelvic floor muscle train-
ing, scheduled voiding regimens, behavioural therapies and medication.  In 
particular: 
• Lifestyle interventions (eg weight loss GoR B) 
• Supervised pelvic floor muscle training for men with post radical prostatectomy 
SUI accelerates recovery time(GoR B) 
• Scheduled voiding regimen for OAB (GoR C) 
• Antimuscarinic/beta 3 agonist drugs for OAB symptoms with or without urgency 
incontinence (GoR B) if the patient has no evidence of significant post-void 
residual urine 
• -adrenergic antagonists (a-blockers) can be added if it is thought that there 
may also be bladder outlet obstruction. (GoR C) 
➢ Should initial treatment be unsuccessful after a reasonable time (for exam-
ple, 8-12 weeks), specialist advice is highly recommended. 
Clinicians are likely to wish to treat the most bothersome symptom first in men 
with symptoms of mixed incontinence. 
 
 
 
  
  
INITIAL MANAGEMENT OF URINARY INCONTINENCE IN MEN 
 
  
HISTORY 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
PRESUMED 
DIAGNOSIS 
Post-micturition 
dribble 
Incontinence on 
exertion (usually 
post-prostatectomy) 
• General assessment  (see relevant chapter) 
• Urinary symptom assessment and symptom score (including bladder diary or 
frequency-volume chart and questionnaire) 
• Assess quality of life and desire for  treatment 
• Physical examination: abdominal, rectal, sacral, neurological 
• Urinalysis ± urine culture -> if infected, treat and reassess 
• Assessment of pelvic floor muscle function 
• Assess post-void residual urine 
SPECIALISED MANAGEMENT 
“Complicated” 
Incontinence: 
• Recurrent or “total” 
incontinence 
• Incontinence associated 
with: 
o Pain 
o Haematuria 
o Recurrent infection 
o Prostate irradiation 
o Radical pelvic surgery 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
• Urethral milking (B) 
• Pelvic floor muscle 
contraction (B) 
URGENCY 
INCONTINENCE 
presumed due to 
detrusor 
overactivity 
DISCUSS TREATMENT OPTIONS WITH THE PATIENT 
• Lifestyle interventions 
• Pelvic floor muscle training ± biofeedback (B) 
• Scheduled voiding/bladder training in OAB (C) 
• Antimuscarinics/beta 3 agonist for OAB ± urgency incontinence (B)   
• -adrenergic antagonists (if suspected bladder outlet obstruction) 
Failure 
Incontinence with 
mixed symptoms 
Urgency / 
frequency, with or 
without urgency 
incontinence 
any other abnormality 
detected e.g. significant 
post void residual 
MIXED 
INCONTINENCE 
Treat most 
bothersome 
symptom first 
STRESS 
INCONTINENCE 
presumed due to 
sphincteric 
incompetence 
  
 
II. URINARY INCONTINENCE IN MEN 
B. SPECIALISED MANAGEMENT 
The specialist may first reinstitute initial management if it is felt that previous 
therapy had been inadequate. 
1. ASSESSMENT 
• Patients with “complicated” incontinence referred directly to specialised 
management, are likely to require additional testing, such as cytology, cys-
tourethoscopy and urinary tract imaging. 
If additional testing is normal then those individuals can be treated for inconti-
nence by the initial or specialised management options as appropriate. 
If symptoms suggestive of detrusor overactivity, or of sphincter incompetence per-
sist, then urodynamic studies are advisable in order to arrive at a precise diagno-
sis, prior to invasive treatment. 
2. TREATMENT 
When basic management has been unsuccessful and if the patient’s incontinence 
markedly disrupts his quality of life then invasive therapies should be considered. 
• For sphincter incompetence the recommended option is the artificial urinary 
sphincter (GoR B). Other options, such as a male sling, may be considered 
(GoR C). 
• For refractory idiopathic detrusor overactivity, (with intractable overactive 
bladder symptoms) the recommended therapies are: Botulinum toxin A (GoR 
B), and SNS (GoR C), 
• When incontinence has been shown to be associated with poor bladder emp-
tying due to detrusor underactivity, it is recommended that effective means 
are used to ensure bladder emptying, for example, intermittent catheterisation 
(GoR B/C). 
• If incontinence is associated with bladder outlet obstruction, then consideration 
should be given to surgical treatment to relieve obstruction (GoR B). -blockers 
and/or 5- reductase inhibitors would be an optional treatment (GoR C).  
• There is increased evidence for the safety of antimuscarinics for overactive 
bladder symptoms in men, chiefly in combination with an -blocker (GoR B).  
  
SPECIALISED MANAGEMENT OF URINARY INCONTINENCE IN MEN 
 
  
HISTORY/ 
SYMPTOM 
ASSESSMENT 
CLINICAL 
ASSESSMENT 
TREATMENT* 
DIAGNOSIS 
Post-prostatectomy 
incontinence 
Incontinence with urgency / 
frequency 
• Consider urodynamics and imaging of the urinary tract 
• Urethrocystoscopy (if indicated) 
“Complicated” Incontinence: 
• Recurrent incontinence 
• Incontinence associated with: 
o Prostate or pelvic irradiation 
o Radical pelvic surgery 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
If initial therapy fails: 
• Artificial urinary 
sphincter (B) 
• Male sling (C) (see 
chapter 13) 
URGENCY INCONTINENCE 
due to detrusor overactivity 
(during filling) 
• -blockers, 5aRI (C) 
• Correct anatomic 
bladder outlet 
obstruction (C) 
• Antimuscarinics/beta 
3 agonists (B) 
with coexisting 
bladder outlet 
obstruction 
MIXED INCONTINENCE 
Treat major component 
first 
STRESS INCONTINENCE 
due to sphincteric 
incompetence 
Consider: 
• Urethrocystoscopy 
• Further imaging 
• Urodynamics 
If initial therapy fails: 
• Botulinum toxin A 
• SNS (B) 
• Correct anomaly 
• Treat pathology 
• Intermittent 
catheterisation 
• Antimuscarinics / 
beta 3 agonists 
with coexisting 
underactive 
detrusor (during 
voiding) 
Lower urinary tract 
anomaly/ pathology 
  
 
III. URINARY INCONTINENCE IN WOMEN 
A. INITIAL MANAGEMENT 
1. INITIAL ASSESSMENT SHOULD IDENTIFY: 
➢ “Complicated” incontinence group. 
Those with pain or haematuria, recurrent infections, suspected or proven voiding 
problems, significant pelvic organ prolapse or who have persistent incontinence or 
recurrent incontinence after pelvic irradiation, radical pelvic surgery, previous in-
continence surgery, or who have a suspected fistula, should be referred to a spe-
cialist. 
➢ Three other main groups of patients should be identified by initial assess-
ment. 
• Women with stress incontinence on physical activity 
• Women with urgency, frequency with or without urgency incontinence: over-
active bladder (OAB) 
• Those women with mixed urgency and stress incontinence 
Abdominal, pelvic and perineal examinations should be a routine part of physical 
examination. Women should be asked to perform a “stress test” (cough and strain 
to detect leakage likely to be due to sphincter incompetence). Any pelvic organ 
prolapse or urogenital atrophy should be assessed. Vaginal or rectal examination 
allows the assessment of voluntary pelvic floor muscle function, an important step 
prior to the teaching of pelvic floor muscle training. 
2. TREATMENT 
➢ For women with stress, urgency or mixed urinary incontinence, initial treat-
ment should include appropriate lifestyle advice, pelvic floor muscle training, 
PFMT), scheduled voiding regimes, behavioural therapies and medication. In 
particular: 
• Advice on caffeine reduction for OAB (GoR B) and weight reduction (GoR A). 
• Supervised pelvic floor muscle training (GoR A), supervised vaginal cones 
training for women with stress incontinence (GoR B). 
• Supervised bladder training (GoR A) for OAB. 
• If oestrogen deficiency and/or UTI is found, the patient should be treated at 
initial assessment and then reassessed after using vaginal oestrogens for a 
suitable period (GoR B). 
• Antimuscarinics/beta 3 agonist for OAB symptoms with or without urgency 
incontinence (GoR A); duloxetine* may be considered for stress urinary incon-
tinence (GoR B) 
PFMT should be based on sound muscle training principles such as specificity, 
overload progression, correct contraction confirmed prior to training and use of “the 
Knack” for 12 weeks before reassessment and possible specialist referral. 
Clinicians are likely to wish to treat the most bothersome symptom first in women 
with symptoms of mixed incontinence. (GoR C). 
➢ Some women with significant pelvic organ prolapse can be treated by vaginal 
devices that treat both incontinence and prolapse (incontinence rings and 
dishes). 
*Duloxetine is not approved for use in United States. In Europe it is approved for 
use in severe stress incontinence (see committee report on pharmacological man-
agement for information regarding efficacy, adverse events, and 'black box' warning 
by the Food and Drug Administration of the United States). 
 
  
  
INITIAL MANAGEMENT OF URINARY INCONTINENCE IN WOMEN 
 
  
HISTORY 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
PRESUMED 
DIAGNOSIS 
Incontinence on physical 
activity 
Incontinence with mixed 
symptoms 
• General assessment (see relevant chapter) 
• Urinary symptom assessment (including bladder diary and questionnaire) 
• Assess quality of life and desire for  treatment 
• Physical examination: abdominal, pelvic and perineal 
• Cough test to demonstrate stress incontinence if appropriate 
• Urinalysis ± urine culture -> if infected, treat and reassess If appropriate 
• Assess oestrogen status and treat as appropriate 
• Assess pelvic floor muscle function 
• Assess post-void residual urine 
•  
SPECIALISED MANAGEMENT 
“Complicated” Incontinence: 
• Recurrent incontinence 
• Incontinence associated with: 
o Pain 
o Haematuria 
o Recurrent infection 
o Significant voiding 
symptoms 
o Pelvic irradiation 
o Radical pelvic surgery 
o Suspected fistula 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
STRESS INCONTINENCE 
presumed due to 
sphincteric incompetence 
• Life style interventions. 
• Pelvic floor muscle training for SUI, MUI, or OAB (A) 
• Bladder retraining for OAB (A) 
• Antimuscarinics/beta 3 agonist OAB ± urgency incontinence (A) or Duloxetine** for SUI (B) 
Failure 
Incontinence / frequency 
with urgency 
• If other abnormality found  e.g. 
• Significant post void residual 
• Significant pelvic organ 
prolapse 
• Pelvic mass 
OAB with or without 
URGENCY 
INCONTINENCE 
presumed due to 
detrusor overactivity 
MIXED INCONTINENCE 
Treat most bothersome 
symptom first 
• Other adjuncts, such as electrical stimulation 
• vaginal devices eg cones (B) 
** Subject to local regulatory 
approval (see black box 
warning). 
  
 
III. URINARY INCONTINENCE IN WOMEN 
A. SPECIALISED MANAGEMENT 
1. ASSESSMENT 
Women who have “complicated” incontinence (see initial algorithm) may need 
to have additional tests such as cytology, urodynamics, cystourethroscopy or uri-
nary tract imaging. If these tests are normal then they should be treated for incon-
tinence by the initial or specialised management options as appropriate. 
• Those women with persistent symptoms despite initial management and 
whose quality of life is impaired are likely to request further treatment. If initial 
management has been given an adequate trial then interventional therapy 
may be desired. When the results of urodynamic testing may change man-
agement, we highly recommend testing prior to intervention in order to diag-
nose the incontinence type and, therefore, inform the management plan. Ure-
thral function testing by urethral pressure profile or leak point pressure is op-
tional. 
• Systematic assessment for pelvic organ prolapse is highly recommended 
and the POP-Q method should be used in research studies. Women with co-
existing pelvic organ prolapse should have their prolapse treated as appropri-
ate. 
2. TREATMENT 
• If stress incontinence is confirmed then the treatment options that are rec-
ommended for patients include the full range of non-surgical treatments, as 
well as colposuspension procedures, (GoR A) and bladder neck/sub-urethral 
sling operations (GoR A). All of these procedures have potential risks and as-
sociated complications which should be discussed with the individual. The cor-
rection of symptomatic pelvic organ prolapse may be desirable at the same 
time. For selected patients injectable bulking agents (GoR B) and the artificial 
urinary sphincter (GoR C) can be considered. 
• Refractory urgency incontinence (overactive bladder) secondary to idio-
pathic detrusor overactivity may be treated by botulinum toxin A (GoR A), sa-
cral nerve stimulation (GoR B) or bladder augmentation/intestinal cystoplasty 
(GoR D). 
• Those patients with voiding dysfunction leading to significant post-void re-
sidual urine (for example, >30% of total bladder capacity) may have bladder 
outlet obstruction or detrusor underactivity. Prolapse is a common reversible 
cause, of voiding dysfunction. 
 
  
  
SPECIALISED MANAGEMENT OF URINARY INCONTINENCE IN WOMEN 
 
  
HISTORY/ 
SYMPTOM 
ASSESSMENT 
CLINICAL 
ASSESSMENT 
TREATMENT* 
DIAGNOSIS 
Incontinence on physical 
activity 
Incontinence with mixed 
symptoms 
• Assess for pelvic organ mobility / prolapse 
• Consider imaging of the UT/ pelvic floor 
• Urodynamics (see notes) 
“Complicated” Incontinence: 
• Recurrent incontinence 
• Incontinence associated with: 
o Pain 
o Haematuria 
o Recurrent infection 
o voiding symptoms 
o Pelvic irradiation 
o Radical pelvic surgery 
o Suspected fistula 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
URODYNAMIC 
STRESS 
INCONTINENCE 
(USI) 
If initial therapy fails**: 
• Stress incontinence 
surgery 
o Bulking agents (B) 
o Tapes and slings (A) 
o Colposuspension (A) 
Bladder outlet 
obstruction 
Incontinence with 
urgency / frequency 
Consider: 
• Urethrocystoscopy 
• further imaging 
• Urodynamics 
DETRUSOR 
OVERACTIvITY 
INCONTINENCE 
(DOI) 
MIXED 
INCONTINENCE 
USI/DOI 
Treat most 
bothersome 
symptom first 
INCONTINENCE 
associated with 
poor bladder 
emptying 
If initial therapy fails*: 
• Botulinum toxin (A) 
• Sacral Nerve Stimulation 
(B) 
• Bladder augmentation (D) 
• Correct anatomic bladder outlet 
obstruction (e.g. genito-urinary 
prolapse) 
• Intermittent catheterisation 
Underactive 
detrusor 
Lower urinary 
tract anomaly / 
pathology 
** Note procedures in 
increasing level of 
invasiveness 
• Correct anomaly 
• Treat pathology 
  
 
IV. FISTULAE 
In the developing world fistulae occur as a consequence of poor perinatal care. 
Despite vast surgical experience in some centres, published research is of low qual-
ity. 
In the developed world, iatrogenic urogenital fistulae are known complications of 
pelvic surgery and oncological treatments such as radiotherapy, chemotherapy or 
a combination of both. In the oncological context, fistulae may also occur as a result 
of primary or recurrent malignancy. The development of fistula following radiother-
apy for primary treatment should trigger a search for evidence of tumour recurrence 
(GoR D). The use of neoadjuvant or adjuvant therapies is likely to be associated 
with a greater risk of fistula development than the primary treatment alone. 
The most common non-obstetric causes of fistulae involving the gastro-intestinal 
tract are diverticular disease, Crohn’s disease, malignancy and radiotherapy. 
1. INITIAL ASSESSMENT  
Early detection of fistulae could be improved by examining all women after their 
delivery, or prevented by Caesarian section for women who suffer prolonged labour 
and who are at risk of developing an obstetric fistula. Associated pathologies should 
be actively searched for and should be taken into account in the treatment plan: all 
components of the ‘obstructed labour injury complex’ should be examined. Preven-
tion by better health education, and by avoiding harmful practices must be encour-
aged. 
Classification of fistulae is recommended. Although many classification systems 
exist, the committee recommends the use of the Goh, WHO or Tafesse classifica-
tion systems (GoR B) 
The formal classification of the fistula should be done under anaesthesia when the 
patient is on the operation table, just before surgery.  
• Leakage of stool, urine, or possibly both is the hallmark sign of a fistula. The 
leakage is usually painless, may be intermittent if it is position dependent, or 
may be constant.  
• CT and cystoscopy appear more consistent in the confirmation and location of 
possible intestino-vesical fistulae, than other investigations (GoR C)  
• Level 3 evidence indicates that the routine use of cystoscopy with dye testing 
at gynaecological surgery has high sensitivity, specificity and negative predic-
tive value in the detection of ureteric injury, although false positive tests do 
occur. (GoR C)  
• Ureteric injury or fistula may be suspected in patients following pelvic surgery 
if a fluid leak or pelvi-calyceal dilatation occurs postoperatively. (GoR D) 
• Uretero-arterial fistula may be suspected in patients presenting with haematu-
ria with a history of relevant pelvic surgery and indwelling ureteric stent. (GoR 
D)  
• Elevated levels of creatinine in drainage fluid following pelvic surgery are sug-
gestive of urine leaking due to a urinary tract injury. (GoR D) 
2. MANAGEMENT OF NEW AND ESTABLISHED VVF 
Management of VVF depends on whether the fistula is diagnosed within a few 
weeks of its occurrence or whether the woman presents late with an established 
fistula.  
Early fistulae are those which are not re-epithelialised, and ischaemic and necrotic 
tissue can be present at the time of examination. There is evidence that early cath-
eter care will result in the cure of a significant minority of VVFs. (GoR C) 
Established fistulae are re-epithelialised and show no oedema, ischaemic changes 
or inflammation. These fistulae and those that fail catheter treatment should be 
treated surgically by an experienced surgeon. (GoR C) 
3. TREATMENT 
If catheter drainage fails, then fistula repair will be necessary. There are certain 
principles behind fistula repair: 
• Necrotic tissue must be removed prior to fistula repair. 
• Fistula repair must only be undertaken by a properly trained surgeon. 
• Adequate post-operative care is essential. 
  
• Proper follow-up should be arranged. 
In principle, most fistulae can be dealt with by the vaginal approach, but an abdom- 
inal approach may be needed in some cases (e.g. concomitant reconstructive pro-
cedures e.g. ureteral reimplantation or bladder augmentation).(GoR C) 
A tension-free single layer closure of the bladder wall and closure of the vaginal 
wall in a separate layer is advocated. A Martius flap in primary fistula repair is not 
recommended. 
When reporting on outcome after fistula repair, authors should make a clear dis-
tinction between fistula closure rates and post-operative incontinence rates and the 
time at which the follow-up was organised. 
Prevention of post-operative stress incontinence must be added to the surgical pro-
cedure if the urethral closing mechanism is involved. This can be done by a good 
repair of the pubocervical fascia and refixation or by adding a sling procedure. 
Attention should be given as appropriate to skin care, nutrition, rehabilitation, coun-
selling and support prior to and following fistula repair. (GoR D) 
There is no proven benefit to delayed repair of vesicovaginal fistulae; the timing of 
repair should be tailored to the individual patient and surgeon requirements, but 
can be undertaken as soon as any oedema, inflammation, tissue necrosis, and in-
fection have resolved. (GoR B) 
There are no high quality data to indicate greater cure rates for any one technique 
as compared to others; level 3 evidence indicates similar success rates for vaginal 
and abdominal, and for transvesical and transperitoneal approaches. (GoR C) 
A variety of interpositional grafts can be used in either abdominal or vaginal   pro-
cedures, although there is little evidence to support their use in any specific setting. 
(GoR C) 
Conventional and robotically-assisted laparoscopic approaches have both been 
shown to be feasible in selected cases; the indications for, or optimal patient for 
these techniques is not yet clear. (GoR C) 
A period of continuous bladder drainage is crucial to successful fistula repair; there 
are no high level data to support any particular type, route, or duration of catheter-
isation. Current practice suggests, 10-14 days for simple and/or post-surgical fistu-
lae; 14-21 days for complex and/or post-radiation fistulae. (GoR D) 
Whilst diversion is used more widely in radiation-associated fistulae of all types as 
compared to non-radiated fistulae, there is low-level evidence that repair proce-
dures can achieve successful fistula closure and continence in appropriately se-
lected cases. (GoR C) 
Where urinary and/or faecal diversions are required, attempts should be made to 
avoid using irradiated tissues wherever possible, and to minimise the potential for 
anastomotic complications. (GoR C) 
There is low-level evidence to support the use of interposition grafts when repair of 
radiation-associated fistulae is undertaken. (GoR C) 
4. MANAGEMENT OF THE COMPLICATIONS OF VVF 
The complications of vesico-vaginal fistulae are many but include: 
• Persistence or recurrence of urinary incontinence 
• Persistence of lower urinary tract symptoms or occurrence of new lower urinary 
tract symptoms, including overactive bladder 
• Urinary tract infections 
• Upper urinary tract symptoms, including loin pain 
• Dyspareunia and sexual dysfunction 
• Infertility 
• Neurological symptoms 
• Psychological problems and mental illness 
 
  
  
 
MANAGEMENT OF VESICOVAGINAL FISTULA 
 
 
 
HISTORY 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
PRESUMED 
DIAGNOSIS 
Leakage of urine from vagina / perineum 
• Clinical examination 
• Urethro-cystoscopy 
• Imaging (X-ray/CT/MRI, US) 
• Evaluate upper urinary tract 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
Recent VVF 
Primary simple 
Consider Catheter, evaluate weekly 
Established VVF 
Primary complex 
Healed Persistant leakage 
Recurrence Post-irradiation 
Vaginal repair 
Consider timing 
Surgical repair 
Consider timing 
Consider interposition 
material 
If small, consider 
catheter, evaluate weekly 
Surgical repair 
6-12 months 
Consider interposition 
material 
Surgical repair 
Consider timing 
Consider interposition 
material 
Assess fistula closure & assess continence status 
  
1. MANAGEMENT OF FISTULAE INVOLVING BOWEL 
• There is limited evidence to support a non-surgical or conservative surgical 
approach in colo-vesical fistulae where there are minimal symptoms or evi-
dence of limited bowel involvement. (GoR C) 
• A one-stage approach to surgery for intestino-vesical fistulae is appropriate in 
many cases, but should be limited to those patients whose nutritional state is 
good, and where there is no evidence of additional intra-abdominal pathology 
(e.g. severe inflammation, radiation injury, advanced malignancy, intestinal ob-
struction) or major co-morbidity. (GoR B) 
• A laparoscopic/robotic approach to one-stage management is feasible, alt-
hough there is no high level evidence to allow comparison of outcomes with 
open surgery. (GoR D) 
2. MANAGEMENT OF URETERIC FISTULAE 
• Surgeons undertaking complex pelvic surgery should be competent at identi-
fying, preserving and repairing the ureter. (GoR D) 
• Ureteric stents are not required as prophylaxis against injury during routine 
gynaecological surgery, while their role in more extensive surgery remains to 
be established. (GoR B) 
• Most upper urinary tract fistulae should be initially managed by conservative or 
endoluminal techniques where such expertise and facilities exist. ( GoR B) 
• Persistent ureterovaginal fistulae should be repaired by an abdominal ap-
proach using open, laparoscopic or robotic techniques according to availability 
and competence. (GoR D) 
• For patients with ureteric fistulae associated with advanced pelvic cancer and 
poor performance status, palliation by nephrostomy tube diversion and endo-
luminal distal ureteric occlusion is an option. (GoR C) 
3. MANAGEMENT OF URETHRO-VAGINAL FISTULAE 
Recommendations 
• Urethrovaginal fistulae are preferably treated by a vaginal approach. (GoR C) 
• A variety of autologous tissue interposition techniques have been described, 
but their value remains uncertain. (GoR C) 
• Urethrovaginal fistulae repair may be complicated by stress incontinence, ure-
thral stricture and urethral shortening necessitating long-term follow-up. (GoR 
C) 
 
  
  
 
MANAGEMENT OF IATROGENIC URETERIC FISTULAE 
 
 
HISTORY 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
PRESUMED 
DIAGNOSIS 
Extra-urethral vaginal urinary leakage and/or signs of ureteric obstruction 
Clinical examination Urethro-cystoscopy Imaging (Xray/CT/ MRI, US) 
Evaluate upper urinary tract obstruction 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
Ureterovaginal fistula 
Endoluminal technique (stenting, 
nephrostomy) for at least 6 weeks 
Unable to stent (initially)... 
Re-evaluate for fistula closure, ureteric obstruction 
Persisting fistula 
or ureteric obstruction 
Ureteric reimplantation (open, laparoscopic or robotic) Healed 
Long-term follow-up for stricture and hydropephrosis 
  
V. PELVIC ORGAN PROLAPSE 
1. INTRODUCTION 
Pelvic organ prolapse includes vaginal and rectal prolapse. Treatment of pelvic or-
gan prolapse is generally reserved for symptomatic prolapse. Clinicians should rec-
ognise that coexistent pelvic floor symptoms are frequently present and that these 
symptoms may or may not be related to the prolapse.  Women with prolapse require 
a careful and detailed initial assessment not only of the prolapse but associated 
bladder, bowel and sexual function.       
2. ASSESSMENT 
Symptom assessment preferably with a validated pelvic floor questionnaire that as-
sesses bladder, bowel, vaginal and sexual function and bothersomeness is re-
quired. (Grade C).   
Physical examination should: 
• Report the most distal site of vaginal descent in relation to a fixed point such 
as the hymen and include an assessment of the anterior posterior and apical 
vagina. While standardised reporting utilising tools such as the Pelvic Organ 
Prolapse Quantification (POP-Q) are encouraged.  The system used to meas-
ure the extent of the prolapse should be documented.  
• Be undertaken in the standing position to evaluate the full extent of the pro-
lapse.  
• Determine if coexistent pelvic pathology is present on careful bimanual exam-
ination. Cytological screening of the cervix should be undertaken if required. 
• The prolapse should be reduced to document the presence of occult stress 
urinary incontinence (see chapter for prolapse and urinary incontinence path-
way). 
• Assess pelvic floor muscle function (see chapter for full review). 
• Determine if epithelial/ mucosal ulceration is present. 
• Evaluate anal sphincter tone and or the presence of rectal prolapse in those 
with bowel symptoms (refer to chapter for pelvic organ prolapse and bowel 
symptom pathway).   
When examination findings of the extent of the prolapse are not consistent with the 
history the examination can be repeated in a few weeks’ time. (GoR C). 
Post void residual should be measured; while most elevated post-void residual 
urines (150mls) resolve with treatment of the prolapse, a specialist consulation is 
required.     
3. MANAGEMENT 
Observation is appropriate when medically safe (GoR C). 
Lifestyle interventions include weight loss, treating constipation, avoiding straining 
at stool and heavy lifting (GoR C). 
Pelvic floor muscle training:  
• Reduces associated pelvic floor symptoms (GoR A). 
• May reduce the symptom of vaginal bulge (GoR C). 
• Does not reduce extent of prolapse on examination based on POP-Q stage 
(GoR B). 
Vaginal Pessary:  when successfully fitted  
• May reduce prolapse symptoms (GoR B) 
• Need to be regularly reviewed (GoR C)  
• Have high rates of discontinuation (GoR C)     
Local Oestrogens are recommended in those with hypo-oestrogenic symptoms and 
in those with urethral prolapse or vaginal ulceration (GoR B) 
Reconstructive surgery is reserved for those with symptomatic prolapse and is 
aimed at correcting the vaginal topography and functional pathology. Please see 
text for full recommendations. 
Obliterative surgery is an important and effective treatment option in those who are 
happy to sacrifice coital activity. (GoR C)
  
 
MANAGEMENT OF PELVIC ORGAN PROLAPSE 
(INCLUDING UROGENITAL PROLAPSE AND RECTAL PROLAPSE) 
  
HISTORY 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
DIAGNOSIS 
Bothersome pelvic organ prolapse 
Symptoms Screening: assess bothersomeness, frequency and severity of urinary, 
ano-rectal, genital and sexual symptoms 
• Urinary: PVR, cough stress test, urinalysis. 
• Physical Examination: Sufficient to determine the site and severity of prolapse 
and detect other significant findings 
o Selective use of urodynamics when results would alter planned treatment. 
o Selective use of upper tract imaging when observation is planned 
• Ano-Rectal: Endoscopy, lower GI tract imaging 
Complex or recurrent prolapse 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
UROGENITAL PROLAPSE WITH OR 
WITHOUT OTHER PELVIC SYMPTOMS 
• Observation 
• Lifestyle interventions 
• Pelvic floor muscle training 
• Pessary 
• Reconstructive surgery 
• Obliterative surgery 
Investigation by specialist 
RECTAL PROLAPSE WITH OR 
WITHOUT OTHER PELVIC SYMPTOMS 
• Observation 
• Lifestyle interventions 
• Transperineal surgery 
• Transabdominal surgery 
Specialist management 
  
PATHWAY FOR THE SURGICAL MANAGEMENT OF PELVIC ORGAN PROLAPSE 
The pelvic organ prolapse (POP) surgery pathway was designed to provide an ev-
idence based guide for both clinicians and women for the surgical management of 
pelvic organ prolapse. Within the pathway green lines highlight the preferred option 
and yellow lines indicate reasonable options.  
An early option in the treatment pathway for women not wanting to preserve sexual 
function is obliterative surgery (colpocleisis) which is an efficacious intervention that 
has low morbidity (LoE 3). 
The majority of women will enter the reconstructive pathway. Apical suspension 
procedures should be considered in all cases with 10-year re-operation rates for 
prolapse being significantly reduced if apical suspensions are performed concomi-
tantly with both anterior and posterior colporrhaphy as compared to those per-
formed without apical support.      
In those undergoing anterior and posterior colporrhaphy the evidence is supportive 
of traditional native tissue suture plications (LoE 1). In the anterior compartment 
permanent mesh could be considered for recurrent cases when the patient under-
stands the risk benefit profile for these interventions and that the data for their use 
is scant.  Evidence is not supportive of biological grafts in the anterior compartment 
(LoE 2). 
In the posterior compartment, fascial plication is superior to site specific native tis-
sue repair (LoE 2) and levatorplasty should be avoided due to higher rates of 
dyspareunia (LoE3). Data are not supportive of biological or permanent mesh 
grafts. Posterior colporrhaphy is superior to transanal repair of rectocele (LoE 1) 
and there is no data to support ventral rectopexy with or without vaginal graft for 
rectocele.  
With recognition of the importance of apical vaginal support in minimising the risk 
of subsequent recurrence, the pathway separates those with post-hysterectomy 
(vault) prolapse from those with uterine prolapse. 
Data are supportive of sacral colpopexy as the preferred intervention for vault pro-
lapse with superior anatomical and functional outcomes when compared to a vari-
ety of vaginal based interventions with and without transvaginal mesh (LoE1). This 
preference is highlighted by a green preferred option arrow in the management 
pathway.  In recognition that not all patients are suitable for sacral colpopexy, a 
yellow reasonable option is included for vaginal based apical support (uterosacral 
or sacrospinous colpopexy). Both uterosacral and sacrospinous colpopexy are 
equally effective vaginal options (LoE 1) and utilisation of transvaginal permanent 
mesh apical support is not supported by the data (LoE1).  
When performing sacral colpopexy the laparoscopic approach is preferred with re-
duced peri-operative morbidity and cost when compared to both the open or robotic 
approach (LoE 2). The yellow reasonable option pathway exists for both open and 
robotic options in recognition of the longer learning curve associated with the lapa-
roscopic approach (LoE3).    
Apical support in those with uterine prolapse can be performed abdominally or vag-
inally and includes options for both uterine preservation (hysteropexy) and hyster-
ectomy, with not insignificant relative contraindications for uterine preservation 
listed in Table 6. In post-menopausal women undergoing hysterectomy, bilateral 
salpingo-oopherectomy (BSO) significantly reduces the rate of ovarian cancer with-
out increased morbidity. In those retaining ovaries at hysterectomy, bilateral salpin-
gectomy also reduces rate of subsequent ovarian cancer.  
Vaginal hysteropexy is equally effective as vaginal hysterectomy with apical sus-
pension and is associated with reduced blood loss and operating time as compared 
to hysterectomy (LoE 1). Vaginal hysterectomy with apical support has a lower re-
operation for prolapse than abdominal sacrohysteropexy (LoE1). Sacrohysteropexy 
has a higher re-operation for prolapse than sacral colpopexy with hysterectomy 
however sacral colpopexy with hysterectomy is not recommended due to the high 
rate of mesh exposure (LoE2).  Supra-cervical hysterectomy at sacral colpopexy 
reduces the rate of mesh exposure associated with hysterectomy and sacral col-
popexy however in a single retrospective study, recurrent prolapse was more com-
mon in the supracervical hysterectomy group. Although those data is not complete, 
vaginal based hysterectomy and hysteropexy with apical support should generally 
be considered as preferred options for uterine prolapse with sacral colpopexy re-
served for vault prolapse.   
Those undergoing prolapse surgery with stress urinary incontinence (SUI) and oc-
cult SUI should generally have continence surgery performed at the time of pro-
lapse surgery (LoE1). Those with prolapse without SUI or occult SUI should not 
undergo continence surgery at time of prolapse surgery (LoE1).  
Based largely upon expert opinion (LoE3) those with prolapse without bowel symp-
toms and those with impaired defaecation with rectocele should undergo prolapse 
surgery as per the above pathway.  Those with POP and impaired defaecation with-
out rectocele, and those with faecal incontinence require colorectal assessment. If 
  
 
rectal prolapse exists, these patients may benefit from combined colorectal and 
gynaecological interventions. Those with significant constipation and prolapse 
should be approached cautiously and may benefit from gastroenterology assess-
ment prior to entering the POP surgery pathway. 
Those undergoing POP surgery generally have improved sexual function post-op-
eratively but a small number undergoing any POP surgery will experience painful 
intercourse post-operatively that may require subsequent intervention (LoE 1). 
  
  
PATHWAY FOR THE SURGICAL MANAGEMENT OF PELVIC ORGAN PROLAPSE 
 
  
Consider CONTINENCE PRODUCTS for temporary support during treatment 
LSC ± repair Sacrospinous 
colpopexy 
Uterosacral 
colpopexy 
Vaginal 
hysterectomy 
Sub-total 
hysterectomy 
ASC 
ASC + 
hysterectomy 
Vaginal SS 
hysteropexy 
Sacral 
hysteropexy 
Hysteropexy Hysterectomy ± 
BSO 
Uterine Vault 
Apical Isolated cystocele Isolated rectocele 
Reconstructive 
surgery 
Obliterative 
surgery 
Sexual Function 
Bladder 
Function 
Bowel Function POP 
SUGERY 
  
 
VI. URINARY INCONTINENCE IN NEUROLOGICAL PATIENTS 
A. INITIAL MANAGEMENT 
1. STRONG GENERAL RECOMMENDATIONS 
• Patients with known neurological disease often need evaluation to exclude 
bladder dysfunction, not only if symptoms occur, but as a standard assessment 
as neurogenic bladder has a high prevalence in the particular disease (for prev-
alence figures see chapter) 
• A possible neurological cause of “idiopathic”incontinence should always be 
considered. Diagnostic steps to evaluate this include basic assessments, such 
as history and physical examination, urodynamics and specialised tests. 
• Incontinence in neurological patients does not necessarily relate to the neuro-
logic pathology. Other diseases such as prostate pathology, pelvic organ pro-
lapse, might have an influence. These factors should be evaluated as potential 
primary or contributory causes. 
• Extensive diagnostic evaluation is often useful and necessary to tailor an indi-
vidual treatment based on complete neurofunctional data. This may not be 
needed in every patient e.g. patients with suprapontine lesions or in patients 
where treatment will consist merely of bladder drainage when the person is frail 
or has limited life expectancy. 
• There is often a need to manage both bladder and bowel dysfunction simulta-
neously 
2. INITIAL ASSESSMENT 
• The management of neurological urinary incontinence depends on an under-
standing of the likely mechanisms producing incontinence. This can in turn de-
pend on the site and extent of the nervous system abnormality. 
• Under current classifications, neurogenic incontinence patients can be divided 
into four groups.  History  and  physical examination  are important in helping 
distinguish these groups: 
o peripheral lesions (as after major pelvic surgery) including those with le-
sions of the cauda equina (eg.lumbar disc prolapse); 
o sacral spinal cord lesions involving the sacral micturition centre 
o suprasacral spinal cord lesions (suprasacral infrapontine spinal cord le-
sions); 
o central lesions of the brain or brain stem (stroke, Parkinson’s disease). 
• Assessment should be made using Questionnaires, urinalysis, bladder diary, 
uroflowmetry with assessment of PVR, and imaging of the urinary tract (ultra-
sonography); all provide basic data for the initial assessment of the NLUTD.  
• Invasive urodynamics should be used as part of the initial assessment in select 
patient populations (SCI, meningomyelocele) 
• Due to increasing data on organ cross-sensitisation and the debilitating effect 
of faecal incontinence on QOL, a history of bowel function should be also in-
cluded 
3. INITIAL TREATMENT 
• Patients with peripheral nerve lesions (e.g. denervation after pelvic surgery) 
and patients with spinal cord lesions (e.g. traumatic spinal cord lesions) should 
receive specialised urological management (GoR A). 
• Initial treatment for patients with incontinence due to suprapontine pathology, 
like stroke; need to be assessed for degree of mobility and ability to cooperate. 
Initial recommended treatments are behavioural therapy (GoR C) and anti-
muscarinic drugs for presumed detrusor overactivity (GoR A). If incontinence 
persists and if operative procedures are not indicated then continence products 
(GoR B) or catheters (GoR C) may be necessary on a long-term basis. These 
can also be necessary in non-cooperative or less mobile patients. 
Pharmacological detrusor relaxation and/or antibiotics may be useful in cases of 
persistent bypass leakage and/or recurrent UTI (patients with continuous drainage) 
In all cases, bowel management should complement management of NLUTD  
  
INITIAL MANAGEMENT OF NEUROGENIC URINARY INCONTINENCE 
 
  
HISTORY, LEVEL 
OF LESION 
CLINICAL 
ASSESSMENT 
MANAGEMENT* 
PRESUMED 
DIAGNOSIS 
Peripheral nerve lesion 
(e.g. radical pelvic surgery). 
Sacral cord/cauda equina lesion (e.g. 
lumbar disc prolapse) 
Suprasacral infrapon- 
tine and pontine lesions 
(e.g. trauma, multiple system atrophy) 
• Further history (bowel. sexual function, fertility issues) 
• General assessment including of home circumstances 
• Urinary diary and symptom score 
• Assessment of functional ability, quality of life and desire for treatment 
• Physical examination: assessment of sensation in lumbosacral dermatomes, anal tone and voluntary contraction of anal sphincter, 
bulbocavernosus and anal reflexes, gait, mobility, contractures, hand fuction. 
• Urine analysis + culture (if infected: treat as necessary) 
• Urinary tract imaging, serum creatinine : if abnormal to specialised management 
• Post void residual (PVR) assessment by abdominal examination or optional by ultrasound 
• Invasive UDS in select patient populations (eg. spinal cord injury, meningomeylocele) 
This assessment will give basic information, but does not yield precise neurourological diagnosis 
* Consider CONTINENCE PRODUCTS for temporary support during treatment  
** Some patients omit IC through personal choice or inability to self catheterise 
***Add complimentary bowel management in all cases 
• Behavioural modification (C) 
• External appliances (B) 
Urinary incontinence associated with 
poor bladder emptying (significant PVR) 
Urinary incontinence due to detrusor overactivity Stress urinary incontinence due to 
sphincter incompetence with 
negligible PVR 
Depending on co-operation and mobility: 
• Behavioural modification, (C) 
• Antimuscarinics (A) /beta 3 agonists (D) 
• Continence products (B) 
• Indwelling catheter (C) 
With negligible PVR 
Suprapontine cerebral 
lesion (e.g. Parkinson’s disease, 
stroke, multiple sclerosis) 
• Intermittent catheterisation ** with or 
without antimuscarinics (A) 
SPECIALISED MANAGEMENT 
Failure Failure 
  
 
VI. URINARY INCONTINENCE IN NEUROLOGICAL PATIENTS 
B. SPECIALISED MANAGEMENT 
1. ASSESSMENT 
• Most patients with neurogenic urinary incontinence require specialised assess-
ment: Invasive urodynamic studies should be used with videourodynamics if 
available when surgical interventions are planned or when the “bladder may 
be unsafe”. 
• Upper tract imaging is needed in some patients and more detailed renal func-
tion studies will be desirable if the upper tract is considered in danger: high 
bladder pressure, upper urinary tract dilation, recurrent or chronic upper tract 
infection, (major) stones, (major) reflux. 
• In patients with peripheral lesions, clinical neurophysiological testing may be 
helpful for better definition of the lesion 
2. TREATMENT 
For specialised management, conservative treatment is the mainstay (GoR A). 
Management of neurogenic urinary incontinence has several options. The algorithm 
details the recommended options for different types of neurological dysfunction of 
the lower urinary tract. The dysfunction does not necessarily correspond to one 
type/level of neurological lesion and is defined best by urodynamic studies. One 
should always ascertain that the management ensures a safe lower urinary tract 
(storage at low pressure and complete emptying) 
Both urinary and bowel function should be assessed together if both systems are 
affected, as symptoms and treatment of one system can influence the other, and 
vice versa (GoR A). 
As therapeutic approaches can differ in various neurological diseases, the most 
prevalent diseases are discussed separately in the chapter 
3. TREATMENT MODALITIES (OFTEN IN COMBINATION) 
➢ Conservative 
• Intermittent catheterisation (GoR A) 
• Behavioural treatment (GoR C) 
• Timed voiding (GoR C) 
• Continence products (GoR B) 
• Antimuscarinics (GoR A) 
• Alpha-1-adrenergic blockers (GoR C) 
• Oral cannabinoid agonists (MS) (GoR C) 
• Beta-3-agonist alone or as an add-on to AM (GoR D) 
• Bladder expression (GoR B) 
• Triggered voiding (GoR C) 
• Indwelling catheter (GoR C) 
➢ Minimally invasive treatments 
• Botulinum toxin for: sphincter (C) detrusor (A) 
• Intravesical electrical stimulation (C) 
• PTNS/TTNS (C) 
• SNM (stable disease only) (C) 
  
➢ Surgical treatment 
• Artificial sphincter (A) 
• Bladder neck sling (B) 
• Sub-urethral tapes (D) 
• Bulking agents (D) 
• Bladder neck closure (D) 
• Stents intraurethral (B) 
• TUI sphincter (B) 
• Sacral deafferentation (B) 
• Sacral anterior root stimulator (B) 
• Enterocystoplasty (B) 
 
  
  
 
SPECIALISED MANAGEMENT OF NEUROGENIC URINARY INCONTINENCE 
 
  
LEVEL AND EXTENT 
OF LESION, HISTORY 
AND CLINICAL 
ASSESSMENT 
SPECIALISED 
ASSESSMENT 
CONSERVATIVE 
TREATMENT 
DIAGNOSIS 
Peripheral nerve lesion (e.g. radical 
pelvic surgery) conus cauda equina 
lesion (e.g. lumbar disc prolapse) 
Suprasacral infrapontine and pontine 
lesion (e.g. trauma, multiple sclerosis) 
• Urodynamic testing (preferably videourodynamics). 
• Urinary tract imaging 
AM antimuscarinics  
SDAF sacral deafferentation 
SARS sacral anterior root 
stimulation 
IC intermittent catheterisation 
PVR postvoid residual 
TUI transurethral incision 
DSD Detrusor-sphincter 
dyssynergia  
IDC indwelling catheter 
BTX-A Botulinum toxin A 
IVES intravesical electrical 
stimulation 
• Timed voiding (C) 
• External appliance (B) 
Incontinence associated with poor 
bladder emptying due to detrusor 
underactivity / sphincter overactivity 
Urodynamic Stress Incontinence due 
to sphincter incompetence 
With DSD 
Suprapontine cerebral lesion (e.g. 
Parkinson’s disease, stroke, multiple 
sclerosis) 
UI due to detrusor overactivity 
No DSD 
• IC (A) 
• -1 blockers (C) 
• Straining* (B) 
• IC + AM (A) 
• IDC + AM (C) 
• Behavioural (C) 
• IC + AM (A) 
• Triggered voiding (C)  
• Indwelling cath. + AM (C) 
• Continence products + AM (B) 
• Artificial sphincter (A) 
• Bladder neck (autologous) 
sling (B) 
• Bulking agents (D) 
• Bladder neck closure (D) 
(Synthetic midurethral tapes 
D)** 
• Stents intraurethral (B) 
• TUI sphincter (B) 
• BTX-A to sphincter ** (C) 
• IVES (C) 
• BTX-A to detrusor ± IC 
• PTNS/TTNS/SNM 
• Enterocystoplasty 
 
** if urethral hypermobility is the cause of USI; the long-term risks of tapes in the neurogenic population are undefined 
* If IC not possible or after sphincter relaxation procedures and with adequate UDS control 
**Intravesical botulinum injections undertaken according to national licensing. Sphincteric botulinum injections are not currently licensed. 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
STOMA/DIVERSION MAY BE AN OPTION IN SELECTED CASES 
• BTX-A to detrusor + IC (A) 
• SDAF + IC (B) 
• SDAF +/- SaRS (B) 
MINIMALLY 
INVASIVE/SURGICAL 
TREATMENT 
  
VII. BLADDER PAIN SYNDROME 
Definition  
Bladder Pain Syndrome (BPS): in the absence of a universally agreed definition, 
the International Society for the Study of Interstitial Cystitis – ESSIC definition is 
given (1).  
ESSIC: Chronic pelvic pain, pressure or discomfort of greater than 6 months dura-
tion perceived to be related to the urinary bladder accompanied by at least one 
other urinary symptom like persistent desire to void or urinary frequency.  Confus-
able diseases as the cause of the symptoms must be excluded. 
There are no published data as to what duration of symptoms indicates that early 
spontaneous resolution of symptoms is unlikely.  While ESSIC arbitrarily uses a 6 
month duration, the American Urological Association Guideline suggests that a 6 
week history is long enough to initiate diagnosis and treatment of BPS (2). Without 
further data, the Consultation cannot make a recommendation and believes that it 
is up to the discretion of the physician and patient as to the proper interval between 
symptom onset and evaluation and diagnosis of a chronic condition. 
1. NOMENCLATURE  
The scientific committee of the International Consultation voted to use the term 
“bladder pain syndrome” for the disorder that has been commonly referred to as 
interstitial cystitis (IC).  The term painful bladder syndrome was dropped from the 
lexicon. The term IC implies an inflammation within the wall of the urinary bladder, 
involving gaps or spaces in the bladder tissue.  This does not accurately describe 
the majority of patients with this syndrome.  Painful Bladder Syndrome, as defined 
by the International Continence Society, is too restrictive for the clinical syndrome.   
Properly defined, the term Bladder Pain Syndrome appears to fit in well with the 
taxonomy of the International Association for the Study of Pain (IASP) (see below), 
and focuses on the actual symptom complex rather than what appears to be long-
held misconception of the underlying pathology.   
Bladder Pain Syndrome (XXIII-2) (per IASP) 
Bladder pain syndrome is the occurrence of persistent or recurrent pain perceived 
in the urinary bladder region, accompanied by at least one other symptom, such as 
pain worsening with bladder filling and day-time and/or night-time urinary fre-
quency. There is no proven infection or other obvious local pathology. Bladder pain 
syndrome is often associated with negative cognitive, and behavioural, sexual, or 
emotional consequences, as well as with symptoms suggestive of lower urinary 
tract and sexual dysfunction. 
The Consultation believes that, based on the pathology and endoscopic finding 
characteristics of the Hunner lesion, the epidemiological pattern that distinguishes 
it from bladder pain syndrome, the clinical response to local treatment of the lesion 
by resection, fulguration, or steroid injection, the response to cyclosporine,  and the 
absence of reports in the literature that non-Hunner patients go on to develop Hun-
ner lesions (ie, the finding of a Hunner lesion does not represent a continuum in the 
natural history of bladder pain syndrome), that the presence of a Hunner lesion 
 
Figure 1 
  
 
should be considered a distinct disease.  It therefore should drop out of the bladder 
pain syndrome construct, much like we do not consider other painful conditions like 
radiation cystitis, ketamine cystitis, or urinary tract infection a part of bladder pain 
syndrome.  
The Consultation concludes that it would be reasonable to designate the Hunner 
lesion in symptomatic patients with the term “interstitial cystitis”, thus indicating a 
true interstitial inflammation.  It would be defined much as Hunner defined it 100 
years ago, and harmonise the largely Asian, European, and North American con-
cepts of interstitial cystitis.  The Consultation will continue to refer to the symptom 
complex as “bladder pain syndrome”.  Hunner lesion will be considered a distinct 
phenotype, but in the future may be classified as a separate disorder entirely, albeit 
with local symptoms that are difficult to differentiate from bladder pain syndrome in 
the absence of endoscopy.  In other words, we may be coming full circle in the 
historical perspective  Figure 1. 
2. HISTORY / INITIAL ASSESSMENT 
Males or females whose symptoms meet the requirements of the definition of blad-
der pain syndrome should be evaluated.  The presence of commonly associated 
disorders including irritable bowel syndrome, chronic fatigue syndrome, and fibrom-
yalgia in the presence of the cardinal symptoms of bladder pain syndrome also 
suggests the diagnosis.  Abnormal gynaecological findings in women and well-char-
acterised, confusable diseases that may explain the symptoms must be ruled out. 
The initial assessment consists of a bladder diary or frequency/volume chart, fo-
cused physical examination, urinalysis, and urine culture.  In the absence of con-
fusable disorders (uncomplicated disease), a diagnosis can be made and treatment 
instituted.  Urine cytology, cystoscopy, and urodynamic evaluation are recom-
mended if clinically indicated and/or the diagnosis is in doubt (complicated disease).  
Patients with urinary infection should be treated and reassessed.  Those with re-
current urinary infection, abnormal urinary cytology, and microscopic or gross hae-
maturia are evaluated with appropriate imaging and endoscopic procedures, and 
only if the findings are unable to explain the symptoms, are they diagnosed with 
BPS. GoR C 
3. INITIAL TREATMENT 
• Patient education, (GoR B) 
• Dietary manipulation, (GoR B) 
• Nonprescription analgesics,  
• Stress reduction,  
• Pelvic floor relaxation techniques comprise the initial treatment of BPS.  In the 
patient with findings suggesting pelvic floor dysfunction, pelvic floor physical 
therapy with myofascial trigger point release and intravaginal Thiele massage 
is often an effective therapeutic intervention.  The treatment of pain needs to 
be addressed directly, and in some instances referral to an anesthesia/pain 
centre can be an appropriate early step in conjunction with ongoing treatment 
of the syndrome.  (GoR A) 
When conservative therapy fails or symptoms are severe and conservative man-
agement is unlikely to succeed,  
• Oral medication (GoR B) or  
• Intravesical treatment can be prescribed.  It is recommended to initiate a single 
form of therapy and observe results, adding other modalities or substituting 
other modalities as indicated by the degree of response or lack of response to 
treatment.    (GoR B) 
4. SECONDARY ASSESSMENT 
If initial oral or intravesical therapy fails, or before beginning such therapy based on 
clinician judgment, it is reasonable to consider further evaluation which can include 
urodynamics, pelvic imaging, and cystoscopy with bladder distention and possible 
bladder biopsy under anaesthesia.   
• Findings of detrusor overactivity suggest a trial of antimuscarinic or beta-3-
agonist therapy.   
• The presence of a Hunner lesion suggests therapy with transurethral resection, 
fulguration of the lesion, or direct steroid injection into the lesion. (GoR B)   
• Bladder distention itself can have therapeutic benefit in 30-50% of patients, 
though benefits rarely persist for longer than a few months.  (GoR C) 
  
5. REFRACTORY BPS 
Those patients with persistent, unacceptable symptoms despite oral and/or in-
travesical therapy are candidates for more aggressive treatment modalities.  Many 
of these are best administered within the context of a clinical trial if possible.  These 
may include  
• Sacral nerve stimulation, (GoR B) 
• Intradetrusor botulinum toxin, (GoR B) 
• Oral cyclosporine A (GoR C), or  
• Clinical trials of newly described pharmacological management techniques.  At 
this point, most patients will benefit from the expertise of an anaesthesia pain 
clinic.   
The last step in treatment is usually some type of surgical intervention aimed at 
increasing the functional capacity of the bladder or diverting the urinary stream.   
• Urinary diversion with or without cystectomy has been used as a last resort 
with good results in selected patients.  Cystectomy and urethrectomy do not 
appear to add any additional efficacy to diversion alone.  
Augmentation or substitution cystoplasty seems less effective and more prone to 
recurrence of chronic pain in small reported series (GoR C)
 
  
  
 
BLADDER PAIN SYNDROME 
 
  
SYMPTOMS 
BASIC 
ASSESSMENT 
1ST LINE RX 
Pain, pressure or discomfort perceived 
to be related to the bladder with at 
least one other urinary symptom (e.g. 
frequency, nocturia) 
History 
• Bladder diary or frequency/volume 
chart 
• Focused physical examination 
• Urinalysis, culture 
Consider CONTINENCE PRODUCTS for temporary support during treatment  
“Uncomplicated BPS” 
Conservative Therapy 
Stress reduction (B) 
Patient education (B) 
Dietary manipulation (B) 
Nonprescription analgesics 
Pelvic floor relaxation 
Pelvic floor physical therapy (A) 
Consult if associated disease 
TREAT AS INDICATED 
Abnormal Normal 
“Complicated” BPS: 
• Incontinence 
• Urinary infection 
• Haematuria 
• Gynaecologic signs/symptoms 
Consider: 
• Urine cytology 
• Further imaging 
• Endoscopy 
• Urodynamics 
• Laparoscopy 
URINARY INFECTION 
Test and reassess 
  
BPS REQUIRING MORE ACTIVE INTERVENTION 
 
  
Note: The only FDA approved therapies are DMSO and pentosan polysulfate. 
Consider CONTINENCE PRODUCTS for temporary support during treatment.  
 
2ND LINE 
TREATMENT 
(no hierarchy implied) 
3RD LINE 
TREATMENT 
5TH LINE 
TREATMENT 
4TH LINE 
TREATMENT 
(no hierarchy implied) 
Consider oral and or intravesical therapies; (B) 
Consider physical therapy; (A) 
Consider cystoscopy with hydrodistention under anaesthesia and treatment of any 
Hunner lesion (B) 
Consider, if not done previously: 
Cystoscopy under anaesthesia with bladder hydrodistension fulguration, resection or 
steroid injection of Hunner lesion (B) 
Sacral Nerve stimulation (B) 
Intra-detrusor botulinum toxin (B) 
Cyclosporine A (C) 
Consider new treatment trials 
Consider:  
Diversion with or without cystectomy (C) 
Substitution cystoplasty 
Improved with acceptable 
quality of life:  
Follow and support 
• Pain management is a primary consideration at every step of the algorithm 
• Patient enrollment in appropriate research trial is a reasonable option at any point 
• Evidence supportingSNS, cyclosporine A, and botulinum toxin for BPS remains limited. These interventions are appropriate only for practitioners with 
experience in treating BPS and who are willing to provide long-term care post-intervention 
•  
  
 
VIII. FAECAL INCONTINENCE IN ADULT PATIENTS 
ASSESSMENT AND MANAGEMENT 
1. INITIAL CLINICAL ASSESSMENT 
Adult patients with faecal incontinence present with a variety of symptom com-
plexes. As many people are reluctant to admit to having faecal incontinence, it is 
important to proactively enquire about it, especially in known high risk groups (such 
as older community-living individuals, post partum women who might have had an 
obstetric injury and patients with loose stools). 
History will include symptoms such as loose stools and urgency, the type and se-
verity of bowel incontinence, systemic disorders, neurological disorders, and ano-
rectal surgeries (e.g., haemorrhoidectomy), obstetric history for women, medica-
tions, diet, chronic straining, cognitive status, and effects of symptoms on quality of 
life. 
2. INITIAL INTERVENTIONS 
• Assessing the type of bowel incontinence may help identify an aetiology. Types 
of bowel incontinence:  Anal incontinence is the involuntary loss of faeces 
and/or flatus and/or mucus). Faecal incontinence is the involuntary loss of fae-
ces. Flatus incontinence is the involuntary loss of rectal gas, which may indi-
cate rectal sensory impairment and/or anal sphincter dysfunction. Mucus in-
continence is the involuntary loss of mucus only (See Figure 1).  
o Some subtypes of faecal incontinence are urgency faecal incontinence, 
which is the involuntary loss of faeces due to an inability to defer defaeca-
tion, once the desire is perceived, for long enough to reach a toilet. Ur-
gency faecal incontinence is often a symptom of external anal sphincter 
dysfunction.  The symptom of urgency does not necessarily result in ur-
gency faecal incontinence. Functional faecal incontinence is due to limita-
tions in mobility or toileting ability or delayed assistance. Passive faecal 
incontinence, incontinence without forewarning, is typically related to in-
ternal anal sphincter dysfunction or poor closure of the external sphincter 
due to rectal prolapse or stage III/IV haemorrhoids.   
• Physical examination will include anal inspection, abdominal palpitation, a brief 
neurological examination, digital rectal examination and usually procto-sig-
moidoscopy or colonoscopy. 
• Further diagnostic testing needs to be considered if the patient has symptoms 
such as an unexplained change in bowel habit, weight loss, anaemia, rectal 
bleeding, severe or nocturnal diarrhoea, or an abdominal or pelvic mass and 
bowel pathology when organic conditions such as cancer, inflammatory bowel 
disease (IBD), a recto-vaginal fistula, full thickness rectal prolapse, or cloacal 
deformity are suspected. Condition specific management is indicated for these 
patients. 
• Reversible factors (such as inadequate access to toilets and side effects of 
medications resulting in loose stools) should be assessed and addressed at 
the outset. 
➢ Some initial management can often be performed in primary care. After envi-
ronmental factors and local or systemic pathology have been excluded, initial 
interventions include: 
• Discussion of options and goals of management with the patient 
• Provision of patient or caregiver information and education (GoR A) 
• Adjustment of diet and fluid advice, fibre intake (GoR A) 
• Establishing a regular bowel habit (GoR C) or urgency training if relevant (GoR 
C) 
• Anti-diarrhoeal medication can help if stools are loose (GoR B) 
• Use of continence products including various types and sizes of absorbent 
pads, briefs, etc., to contain leaked faeces and prevent skin damage 
• Provide advice on practical coping skills when incontinence occurs (GoR C) 
  
3. SECONDARY INTERVENTIONS 
• If initial interventions fail to improve symptoms after 8-12 weeks, consideration 
should be given to referral to an incontinence specialist (e.g., gastroenterolo-
gist, continence nurse, advisor physiotherapist, or colorectal surgeon) for other 
interventions or further assessment. 
• Pelvic floor muscle training (PFMT) – contraction of pelvic floor muscles, mul-
tiple times per day to improve strength of contraction and increase awareness 
of anorectal muscle function. (GoR C) 
• Biofeedback therapy – behavioural treatment designed to enhance the 
strength of sphincter contraction and improve rectal sensation using special-
ised equipment. Biofeedback therapy can be combined with PFMT to improve 
strength. (GoR B) 
• Transanal Irrigation to maximise bowel emptying and minimise faecal inconti-
nence  primarily in patients with incomplete elimination, passive faecal inconti-
nence, or faecal incontinence with defaecation difficulty, (GoR C) 
4. SECONDARY ASSESSMENT 
• A variety of anorectal investigations, including manometry, anal ultrasound, 
and possibly MRI, defaecography, and neurophysiological testing can help to 
define structural or functional abnormalities of anorectal function and guide 
management if initial and/or secondary interventions are ineffective 
5. TERTIARY REFERRAL, SURGICAL OR MULTI-
DISCIPLINARY CONSULTATION 
• Faecal incontinence that fails to respond to initial and secondary management 
requires specialised consultation by a gastroenterologist, colorectal surgeon, 
urogynaecologist, and/or a multi-disciplinary team 
  
  
 
ASSESSMENT AND CONSERVATIVE MANAGEMENT OF FAECAL INCONTINENCE 
 
  
Identification 
Active case finding or patient presents 
with faecal incontinence (C) 
Initial Clinical Assessment  
• History (C) 
• Physical exam (C) 
• Medication and diet review (C) 
• Assessment of impact on quality of life 
(C) 
• Proctosigmoid-oscopy and/or 
colonoscopy as needed (C) 
Secondary Interventions 
• PFMT +/ (B) 
• Biofeedback (A) 
• Incontinence products such as an anal 
plug or insert (B) 
Condition Specific 
Assessment and 
Management  
For cancer, IBD, impaction, full 
thickness rectal prolapse, recto-
vaginal fistula, cloacal deformity (C) 
Secondary Assessment 
• Manometry and/or Ultrasound (B/C) 
• Possible additional test 
• MRI (C) 
• Defaecography (B/C) 
• Neuro-physiology testing (C/D) 
Incontinence Specialist (C) 
Address Reversible Factors  
Toilet access, medication side effects, loose stools, etc. (C) 
Initial Interventions 
• Discussion of options and patient’s goals of management (B/C) 
• Education of patient and/or caregiver (B/C) 
• Diet and eating pattern modifications (B), and dietary fibre supplements (A) 
• Medications (loperamide) (B) 
• Bowel habit training (C) 
• Transanal irrigation (C) 
• Incontinence products such as pads for containment (B) 
• Practical advice for coping (locating toilets, carrying cleansing kits, etc.) (C) 
Tertiary 
Referral, surgical and/or multi-discipline consult (C) 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
  
VIII. FAECAL INCONTINENCE IN ADULT PATIENTS 
SURGERY FOR FAECAL INCONTINENCE 
1. PATIENT ASSESSMENT 
• The reader is referred to the relevant chapter sections in “Dynamic Testing” 
and “Conservative Treatment for Faecal Incontinence.” In general, patients re-
ferred for surgical management of faecal incontinence must either have failed 
conservative therapy or not be candidates for conservative therapy due to se-
vere anatomic or neurological dysfunction. 
• Prior to surgical management of faecal incontinence, the integrity of the anal 
sphincter complex should be assessed. This assessment is best performed 
with endoanal ultrasound, though pelvic MRI may also be useful. Ancillary tests 
include anal manometry, electromyography, and defaecography. 
• If the patient has persisting faecal incontinence, he or she should undergo re-
peat assessment, including endoanal ultrasound. 
2. SPECIALISED MANAGEMENT 
• The surgical approach is influenced by the presence and magnitude of an an-
atomical anal sphincter defect. If no defect is present, or if the sphincter defect 
is minimal, options include SNS and biomaterial injection therapy. 
• Acute anal sphincter repair is usually required following obstetric or direct 
trauma. End to end or overlapping repair may be performed. When possible 
the internal anal sphincter should be separately repaired. (GoR C) 
• Patients with rectal prolapse, rectovaginal fistula or cloacal deformity often 
have associated faecal incontinence. Initial therapy should be directed at cor-
rection of the anatomical abnormality. (GoR C) 
• For patients with moderate sphincter defects, sphincteroplasty, SNS or bio-
material injection therapy can each be considered. For patients with large 
sphincter defects (>120 degrees), sphincteroplasty is likely to be the best op-
tion, though a PNE trial for SNS can be considered. (GoR C) 
• Patients with sphincter defects of greater than 180° or major perineal tissue 
loss require individualised treatment. In some cases, initial reconstruction can 
be performed. Should incontinence persist, alternatives include stimulated 
muscle transposition (usually gracilloplasty) artificial anal sphincter implanta-
tion, or SNS. (GoR C) 
3. SALVAGE MANAGEMENT 
• For patients who remain incontinent following sphincteroplasty, repeat endo-
anal ultrasound should be undertaken to reassess the status of the repair. If 
no defect is present, or if the sphincter defect is minimal, options include SNS 
and biomaterial injection therapy. If there is a large persisting sphincter defect, 
repeat sphincteroplasty can be considered. (GoR C) 
• Patients who have failed SNS can be considered for biomaterial injection ther-
apy or sphincteroplasty if a sphincter defect is present. Other alternatives in-
clude stimulated graciloplasty and implantation of an artificial anal sphincter. 
(GoR C) 
• Patients who fail surgical therapy for faecal incontinence, or who do not wish 
to undergo extensive pelvic reconstruction, should consider placement of an 
end sigmoid colostomy. (GoR C) While this procedure does not restore conti-
nence, it does restore substantial bowel control and appears to improve social 
function and quality of life. Novel therapies can also be considered under pro-
tocol:  PTNS, the magnetic anal sphincter, SECCATM, vaginal pessary (Eclip-
seTM) and sling procedures. (GoR D) 
4. SPECIAL SITUATIONS 
• Individuals with congenital abnormalities may be amenable to surgical repair. 
Often this will involve both laparoscopic abdominal and perineal approached. 
Poor functional outcomes may be treated by an Antegrade Continence Enema 
(ACE) procedure or colostomy. Patients with cauda equina type neurological 
disorders, either congenital or acquired, should be considered for an ACE pro-
cedure or colostomy. (GoR C)  
  
 
SURGICAL MANAGEMENT OF FAECAL INCONTINENCE 
 
  
ACE Colostomy 
Repeat evaluation 
Follow up 
Severe spinal cord 
impairment 
Yes No 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
MDT-REVIEW: 
CLINICAL, RADIOLOGICAL AND 
PHYSIOLOGICAL DATA 
Rectal prolapse 
Rectovaginal fistula 
Cloacal deformity 
Correction of anatomic 
abnormality 
Rectal evacuation 
disorder 
Sphincter defect > 180o 
or significant perineal 
tissue loss 
Sphincter defect 
120o-180o 
Sphincter defect  
< 120o 
No sphincter defect 
• Rectocele repair  
• Ventral rectopexy 
• Sphincteroplasty +/- 
vaginal and perineal 
reconstruction 
• Stimulated graciloplasty 
• Artificial anal sphincter 
• SNS 
• Colostomy  
• Sphincteroplasty 
• SNS 
• Colostomy 
• SNS 
• Sphincteroplasty 
• BI 
• Colostomy 
• SNS 
• BI 
• Colostomy 
Symptom improvement 
Novel therapies: 
• Magnetic anal sphincter 
• Puborectal sling 
• Radiofrequency energy treatment 
• Stem cell therapy 
• Vaginal pessary - Eclipse™ ACE Antegrade Continence Enema  
BI Biomaterial Injection 
MDT Multi-Disciplinary Team 
SNS Sacral Nerve Stimulation 
  
IX. FAECAL INCONTINENCE IN NEUROLOGICAL PATIENTS 
A. INITIAL MANAGEMENT 
➢ Patients with known neurological disease may present with symptoms related 
to neurological bowel dysfunction, such as; difficulty in defaecation, constipa-
tion and faecal incontinence which disturb their activities of daily living and im-
pair quality of life. Many have permanent impairments and functional limitations 
and disabilities, which are due to neurological deficits and complications 
1. INITIAL ASSESSMENT 
➢ The history should include: 
• Neurological diagnosis and functional level 
• Previous and present lower gastrointestinal (LGIT) function and disorders 
• Severity of neurogenic bowel dysfunction 
• Current bowel care and management including diet, fluid intake, medications 
affecting bowel functions 
• Co-morbidity / complication e.g., urinary incontinence, autonomic dysreflexia, 
pressure ulcers, sexual dysfunction 
• Patient’s satisfaction, needs, restrictions and quality of life 
• Environmental factors and barriers and facilitators to independent bowel man-
agement. 
➢ Physical examination: 
➢ Cognitive function; motor, sensory and sacral reflexes – voluntary anal sphinc-
ter contraction, deep perianal sensation, anal tone, anal and bulbo- cavernosus 
reflexes 
➢ Spasticity of the lower limbs 
➢ Abdominal palpation for faecal loading and rectal examination 
➢ Functional assessment: 
• Hand and arm use, fine hand use, mobility – maintaining body position, transfer 
and walking ability. 
➢  Environmental factors assessment: 
• toilet accessibility; devices for bowel care and mobility; caregiver support and 
attitude; 
2. BASIC INVESTIGATIONS 
Stool examination, plain abdominal X-Ray 
3. INITIAL TREATMENTS 
• Patient education and goals-setting to achieve complete defaecation on a reg-
ular basis and faecal continence based on right time, right place, right trigger 
and right consistency 
• Adequate fibre diet and fluid intake; appropriate trigger according to preserva-
tion of sacral (anorectal) reflex – digital rectal stimulation (GoR C); suppository 
and enema (GoR B); if no anorectal reflex, manual evacuation (GoR B); ab-
dominal massage (GoR C) can also be helpful 
• Prescribe medications – stool softener, laxative, prokinetic agents, anti-diar-
rhoeal drugs as neccessary 
• Assistive techniques may be necessary for 
o Defaecation – transanal irrigation (GoR A) 
o For incontinence – anal plug (GoR C) 
The algorithm does not apply to management in acute neurological patients that 
need regular bowel emptying. 
 
  
 
INITIAL MANAGEMENT OF NEUROGENIC FAECAL INCONTINENCE 
 
  
HISTORY, LEVEL 
OF LESION 
CLINICAL 
ASSESSMENT 
TREATMENT* 
PRESUMED 
DIAGNOSIS 
Sacral cord/cauda equina lesion (e.g. 
lumbar disc prolapse). Peripheral 
nerve lesion (e.g. radical pelvic 
surgery) 
Suprasacral infrapontine and pontine 
lesion (e.g. trauma, multiple sclerosis) 
• History taking including diagnosis, pre-morbid bowel function and sensation and their disorders, current bowel and bladder 
programme, co-morbid diseases/disorders, QOL and  needs 
• Physical & neurological examination including cognitive function, voluntary anal contraction, perianal sensation, sacral reflexes, 
digital rectal examination, abdominal palpation for faecal impaction 
• Functional assessment including hand and arm use, fine hand use, balance, transfer and  walking 
• Environmental factors assessment including toilet accessibility, assistive device, caregivers’ support and attitude 
• Basic investigation: stool exam, plain film abdomen in selected patients (diarrhoea, impaction not felt on rectal examination) 
This assessment will give basic information but does not permit a precise diagnosis of neurogenic bowel dysfunction 
• Manual evacuation 
• Assistive device – anal plug 
• Mini-enema, transanal irrigation 
• Suppository 
• Biofeedback 
Incontinence due to sphincter 
incompetence 
Suprapontine lesions 
(e.g. Parkinson’s) 
• Digital rectal stimulation  
• Chemical stimulant, 
suppository,mini-enema, stool 
softener, laxative, prokinetics, and 
• Transanal irrigation could be given 
by patient/caregiver;  biofeedback 
by patient 
SPECIALISED MANAGEMENT PREFERABLE FOR MORE " TAILORED " TREATMENT 
NECESSARY IN 
ALL 
Incontinence due to lack of cognitive 
function, sensory awareness 
disorders, unable to control by vol- 
untary anal contraction 
"false incontinence" due to faecal 
impaction 
• Faecal disimpaction: 
• Oral PEG plus enemas or transanal 
irrigation 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
Patient education, adequate fibre diet and fluid intake; regular bowel care, preferably ± 3 times a week 
  
IX. FAECAL INCONTINENCE IN NEUROLOGICAL PATIENTS 
B. SPECIALISED MANAGEMENT 
1. ASSESSMENT 
• Some patients with neurogenic faecal incontinence will need specialised as-
sessment, especially if initial management is unsuccesful to look for comorbid-
ity and certainly before performing invasive treatment 
• Do not assume that all symptoms are due to neuropathy, e.g. women with neu-
rological pathology might have had childbirth injury to the sphincter 
• Special investigations: manometry, endoanal ultrasound, (dynamic) MRI, (nee-
dle) EMG. These specific bowel functional tests and electro-diagnostic tests 
must be considered optional, as their value in neurological pathology is not 
sufficiently demonstrated so far. 
2. TREATMENTS 
 
➢ Conservative treatment for neurological faecal incontinence is also the main-
stay for specialised management, (GoR C).   
➢ Management of neurological incontinence does not include very extensive 
treatment modalities and many conservative interventions are still empirical. 
• Transanal irrigation (GoR B). 
• Electrical stimulation sphincter, (GoR C). 
• Percutaneous neuromodulation and sacral nerve stimulation : further research 
is required (GoR D). 
➢ Surgical management of neurogenic faecal incontinence has different options 
which need a very strict patient selection 
• Antegrade Continence Enema ACE (GoR C). 
• Artificial bowel sphincter or FENIX procedure (GoR C). 
• Sacral Anterior Root Stimulation SARS (GoR C). 
• Botulinum Toxin (GoR C). 
• Neuromodulation (GoR C). 
➢ It is recommended that urinary and bowel function are assessed simultane-
ously if both systems are affected, as symptoms and treatment of one system 
can influence the other and vice versa (GoR A). 
➢ As the therapeutic approach can differ in different neurological diseases, the 
most prevalent diseases are discussed separately in the chapter. 
  
  
 
 SPECIALISED MANAGEMENT OF NEUROGENIC FAECAL INCONTINENCE 
 
  
PRIMARY ASSESSMENT, 
HISTORY, LEVEL AND 
EXTENT OF LESION, 
CLINICAL ASSESSMENT 
SPECIALISED 
ASSESSMENT 
CONSERVATIVE 
TREATMENT 
DIAGNOSIS 
Sacral cord/cauda equina lesion (e.g. 
lumbar disc prolapse). Peripheral 
nerve lesion (e.g. radical pelvic 
surgery) 
Suprasacral infrapontine and pontine 
lesion (e.g. trauma, multiple sclerosis) 
• Functional bowel testing / functional imaging 
• Consider neurophysiological testing and anorectal manometry. 
• Transanal irrigation (B) 
• Electrical stimulation of sphincter (C), 
• Percutaneous neuromodulation: further studies 
Faecal Incontinence through loss of bowel sensation, sphincter deficiency 
or severe rectal prolapse 
Suprapontine lesions 
(e.g. Parkinson’s) 
STOMA/DIVERSION MAY BE AN OPTION IN SELECTED CASES 
SURGICAL 
TREATMENT 
Faecal impaction 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
• ACE (C) 
• Artificial bowel sphincter or FENIX procedure (C) 
• SARS (C) 
• Botulinum Toxin for anal sphincter spasticity (C) 
• Neuromodulation (C) 
Faecal disimpaction 
Failure 
consider 
Failure consider 
ACE Antegrade Continence Enema  
SARS Sacral Anterior Root Stimulation 
  
X. URINARY AND FAECAL INCONTINENCE IN FRAIL OLDER MEN AND WOMEN 
• There is no reason to suspect why interventions which have proven efficacy in 
the community dwelling elderly should not also be effective in frail older people. 
Clinicians should, however, take due regard of the practicality, potential bene-
fits and dangers of employing any single intervention in this population.  
• Frail older people do require a different approach addressing the potential role 
of co-morbid disease, current medications (prescribed, over the counter and/or 
naturopathic), and functional and cognitive impairment in urinary and faecal 
incontinence.  
• The extent of the investigation and management should take into account the 
degree of bother to the older person and/or caregiver, the goals for care, the 
degree that the older person is able to undertake any intervention and the over-
all prognosis and life expectancy.  
• Effective management to meet the goals of care should be possible for most 
frail older people. 
1. HISTORY AND SYMPTOM ASSESSMENT 
• Active case finding for urinary and faecal incontinence should be done in all 
frail older people (GoR A).  
• History should include comorbid conditions and medications that could cause 
or worsen incontinence.  
• Physical examination should include a rectal examination for faecal loading or 
impaction (GoR C), functional assessment (mobility, transfers, manual dexter-
ity, dressing and undressing ability, ability to toilet) (GoR A), a screening test 
for depression (GoR B), and cognitive assessment (to assist in planning and 
management, (GoR C)).  
• The mnemonic DIPPERS (see urinary and faecal incontinence algorithms) co-
vers some of these comorbid conditions. Note that urogenital atrophy does not, 
in itself, cause urinary incontinence and should not be treated for this purpose 
(GoR B). 
• The patient and / or caregiver should be asked about the degree of bother of 
urinary incontinence and/or faecal incontinence(GoR B); goals for urinary and 
faecal incontinence care (dryness, decrease in specific symptoms, quality of 
life, reduction of comorbidity, lesser care burden) (GoR B); and likely coopera-
tion with management (GoR C). 
• Evaluation for bowel “alarm” symptoms (rectal bleeding, positive blood screen-
ing from stool studies, obstructive symptoms, recent onset of constipation, 
weight loss, and a change in stool calibre) will need more extensive evaluation 
(GoR A) 
• Urinalysis is recommended for all patients, primarily to screen for haematuria 
(GoR C). 
•  Treatment of otherwise asymptomatic bacteriuria/pyuria is not beneficial (GoR 
C), and it may cause harm by increasing the risk of antibiotic resistance and 
severe adverse effects. e.g., Clostridium difficile colitis (GoR C). 
• Stool studies may not be needed in all patients with faecal incontinence. Pa-
tients with diarrhoea, especially those with more acute onset diarrhoea, may 
need to be tested for infectious causes of their diarrhoea. Other stool studies 
could involve testing for malabsorption syndromes. 
• The utility of the Clinical Stress test in this population is uncertain (GoR D). 
• Wet checks can assess urinary incontinence frequency in long-term care resi-
dents (GoR C). 
• A post voiding residual volume (PVR) test is impractical in many care settings 
and there is no consensus for the definition of what constitutes a “high” PVR in 
any population. A PVR measurement is not recommended in the routine initial 
assessment of frail older people with urinary incontinence. 
• However, there is compelling clinical experiential evidence for PVR testing in 
selected frail older people with: diabetes mellitus (especially long standing); 
prior urinary retention or high PVR; recurrent UTIs; medications that impair 
bladder emptying (e.g., opiates); severe constipation; persistent or worsening 
urgency urinary incontinence despite antimuscarinic/beta-3-agonist treatment; 
or prior urodynamics showing detrusor underactivity and/or bladder outlet ob-
struction (GoR C). Treatment of contributing comorbidity may reduce PVR. 
Trial with catheter may be considered for PVR > 200-500 ml if the PVR is felt 
to contribute to UI or urinary frequency (GoR C). 
  
 
• Nocturia Assessment of frail elders with bothersome nocturia should identify 
potential underlying causes including nocturnal polyuria (by bladder diary/fre-
quency- volume chart or wet checks; oedema on examination) (GoR C),pri-
mary sleep problems (e.g., sleep apnoea); and low voided volumes (e.g., from 
high PVR). 
• Stool impaction/loading. If suspected on digital rectal examination, an ab-
dominal x-ray may be necessary to further evaluate the degree and location of 
impaction/loading in frail older adults. 
2. CLINICAL DIAGNOSIS 
The most common types of Urinary Incontinence in frail older people are urgency, 
stress, and mixed urinary incontinence. Frail older people with urgency urinary in-
continence also may have detrusor underactivity during voiding with a high PVR 
but without outlet obstruction. There is no evidence that antimuscarnincs are less 
effective or cause retention in this situation (GoR D). 
The most common types of faecal incontinence in frail older people are related to 
urgency and passive leakage. Passive leakage can refer to leakage, seepage and 
staining following bowel movements that are not associated with faecal urgency 
and may also occur with faecal impaction. Because constipation and impaction of-
ten contribute to faecal incontinence in older adults, these are considered sepa-
rately in the algorithm. 
3. INITIAL MANAGEMENT 
• Initial treatment should be individualised and influenced by goals of care, treat-
ment preferences and estimated remaining life expectancy, as well as the most 
likely clinical diagnosis (GoR C). In some frail older persons the only possible 
outcome may be containment; management with continence products, espe-
cially for people with minimal mobility (require assistance of > 2 people to trans-
fer), advanced dementia (unable to state their name), and /or nocturnal urinary 
and faecal incontinence. 
• Conservative and behavioural therapy for UI includes lifestyle changes (GoR 
C), bladder training for more fit alert persons (GoR B), and prompted voiding 
for frailer, more impaired older people (GoR A). 
• For the select cognitively intact older person with UI or FI, pelvic floor muscle 
therapy can be considered, but there are few studies (GoR C). Antimuscarinics 
may be added to conservative therapy of urgency UI (GoR A-C, depending on 
agent). 
• For the select cognitively intact older with FI, biofeedback may be considered, 
but few studies exist among frail older adults. 
• Alpha-blockers may be cautiously considered in frail men with suspected pros-
tatic obstruction (GoR C). All drugs should be started at the lowest dose and 
titrated with regular review until either care goals are met or adverse effects 
are intolerable. 
• DDAVP (vasopressin) has a high risk of severe hyponatraemia in frail older 
persons and should not be used outside specialist centres .or without very 
careful monitoring and long term followup (GoR A). 
• Improving stool consistency can be done with dietary fibre and supplem.entary 
fibre in older adults (GoR C). In older adults with diarrhoea, loperamide may 
be considered at low doses to improve stool consistency. However, close mon-
itoring for constipation and impaction is needed. 
4. ONGOING MANAGEMENT AND REASSESSMENT 
Optimal urinary and faecal incontinence management is usually possible with the 
above approaches. If initial management fails to achieve the desired goals, the next 
steps are reassessment and treatment of contributing comorbidity and/or functional 
impairment. 
5. SPECIALISED MANAGEMENT 
If frail older people have either other significant factors (e.g., pain, haematuria, 
bowel “alarm” symptoms), UI or FI symptoms that cannot be classified as urgency, 
stress, or mixed or overflow or other complicated comorbidity which the primary 
clinician cannot address (e.g. dementia, functional impairment), then specialist re-
ferral should be considered. Referral may also be appropriate when there is been 
insufficient response to initial management. The type of specialist will depend on 
local resources and the reason for referral: surgical specialists (urologists, gynecol-
ogists, colorectal surgeons), gastroenterologists, geriatricians or physical therapist 
(functional and cognitive impairment); or continence nurse specialists (homebound 
patients). Referral decisions should consider goals of care, patient/caregiver desire 
for invasive therapy and estimated remaining life expectancy. 
  
Age per se is not a contraindication to UI or FI surgery (GoR C), but before sur- 
gery is considered, all patients should have: 
• Evaluation and treatment for any comorbidity, medications, and cognitive or 
functional impairments contributing to UI that could compromise surgical out-
come (e.g., dementia that precludes patient ability to use artificial sphincter) 
(GoR C). 
• Adequate trial of conservative therapy, including pharmacological therapies 
where relevant (GoR C). 
• Discussion (including the caregiver) to ensure that the anticipated surgical out-
come is consistent with goals of care in the context of the patient’s remaining 
life expectancy (GoR C). 
• Urodynamic testing or anorectal manometry, because clinical diagnosis may 
be inaccurate (GoR B). 
• Preoperative assessment and perioperative care to establish risk of, and to 
minimise the risk of common geriatric post-operative complications such as 
delirium and infection (GoR A), dehydration and falls (GoR C). 
  
  
 
 MANAGEMENT OF URINARY INCONTINENCE IN FRAIL OLDER MEN & WOMEN 
 
 
• Delirium 
• Infection 
• Pharmaceuticals 
• Psychological 
• Excess urine output 
• Reduced mobility 
• Stool impaction (and their 
factors) 
(avoid overtreatment of 
asymptomatic bacteriura (C)) 
HISTORY/ SYMPTOM 
ASSESSMENT 
CLINICAL 
ASSESSMENT 
INITIAL 
MANAGEMENT* 
CLINICAL DIAGNOSIS 
Active case finding in all frail elderly people (A) 
• Assess, treat and reassess potentially treatable conditions, 
including relevant comorbidities and ADLs (see text) (A-C) 
• Assess Qol, desire for Rx, goals for Rx, patient & caregiver 
preferences (C) 
• Targeted physical examination (cognition, mobility, 
neurological and digital rectal examination) (A-C) 
• Urinalysis (C) 
• Consider bladder diary or wet checks, especially if nocturia is 
present. PVR in specific patients (see text) (C) 
UI associated with: 
• Pain 
• Haematuria 
• Recurrent symptomatic UTI 
• Pelvic mass 
• Pelvic irradiation 
• Pelvic / LUT surgery 
• Prolapse beyond introitus  
(women) 
• Suspected fistula 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
URGENCY UI* 
• Lifestyle interventions 
(B-C) 
• Behavioural therapies (B) 
• Consider trial of 
antimuscarinic drugs / 
beta 3 agonist (A-C) 
STRESS UI* SIGNIFICANT PVR* 
• Treat constipation (C) 
• Review medications 
• Consider trial of alpha-
blocker (men) (C) 
• Catheter drainage if PVR 
200-500 ml, then reassess 
(see text) (C) 
• Lifestyle interventions 
(B-C) 
• Behavioural therapies (B) 
(See text) 
ONGOING 
REASSESSMENT AND 
MANAGEMENT 
If insufficient improvement, reassess for and treat contributing comorbidity ± functional 
impairment 
If continued insufficient improvement, or severe associated symptoms are present, consider 
specialist referral as appropriate per patient preferences and comorbidity (see text) 
These diagnoses may overlap 
in various combinations, e.g., 
Mixed UI, DHIC (see text) 
(If Mixed UI, initially treat most 
bothersome symptoms) 
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Rx reversible causes: 
• Delirium 
• Infection 
• Pharmaceuticals 
• Psychological 
• Excess stool output 
(diarrhoea) 
• Reduced mobility 
• Stool impaction (and their 
factors) 
• asymptomatic bacteriura 
CLINICAL 
ASSESSMENT 
INITIAL 
MANAGEMENT* 
CLINICAL DIAGNOSIS 
• Assess, treat and reassess potentially treatable conditions, 
including relevant comorbidities and ADLs (see text) (A-C) 
• Assess Qol, desire for Rx, goals for Rx, pt & caregiver 
preferences (C) 
• Targeted physical examination (cognition, mobility, 
neurological and digital rectal examination) (A-C) 
• Urinalysis (C) 
• Consider bowel diary and clean checks (C) 
* Consider CONTINENCE PRODUCTS for temporary support during treatment 
Urge Fl** 
• Lifestyle interventions 
(B-C) 
• Behavioural therapies (B) 
• Biofeedback (C) 
• Improve stool consistency 
(C) 
Passive Fl* Constipation/ faecal 
Impaction* 
• Treat constipation (osmotic 
laxatives) If impacted, 
glycerine or Bisacodyl sup- 
positories. Phospate enemas if 
severe. (B-C) 
• Review  medications that may 
contribute to constipation (C) 
• Consider biofeedback if 
dyssynergic defaecation is 
suspected (C) 
• Lifestyle interventions 
(B-C) 
• Behavioural therapies (B) 
• Biofeedback (C) 
• Improve stool consistency 
(C) 
ONGOING 
REASSESSMENT AND 
MANAGEMENT 
If insufficient improvement, reassess for and treatment of contributing comorbidity ± 
functional impairment 
If continued insufficient improvement, or severe associated symptoms are present, consider 
specialist referral as appropriate per patient preferences and comorbidity (see text) 
** These diagnoses may overlap 
in various combinations, e.g., 
Urgency-related,passive/seepage, 
and impaction (see text) 
 
HISTORY/ SYMPTOM 
ASSESSMENT 
Active case finding in all frail elderly people (A) FI associated with: 
• Pain 
• Rectal bleeding 
• Change in stool calibre 
• Weight loss 
• Chronic diarrhoea 
• Faecal impaction 
• Inflammatory bowel disease 
• Pelvic irradiation 
• Malabsorption syndromes 
• Prolapse beyond introitus 
(women) 
• Suspected fistula 
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4. RECOMMENDATIONS FOR 
FURTHER RESEARCH IN 
EPIDEMIOLOGY 
1. Longitudinal study designs are needed to: (i) es-
timate the incidence and remission rates of uri-
nary incontinence (UI) anal incontinence (AI) and 
pelvic organ prolapse (POP) and to (ii) describe 
the natural course of these conditions and (iii) to 
investigate risk factors and possible protective 
factors. In addition, similar studies regarding 
other lower urinary tract symptoms (LUTS) 
should be initiated. 
2. Although there is now more information regard-
ing prevalence, incidence, and other epidemio-
logical data in developing countries, further infor-
mation is still needed. It is recommended that 
fundamental research regarding prevalence, in-
cidence and other epidemiological data in devel-
oping countries should be encouraged, and tai-
lored to the cultural, economic and social envi-
ronment of the population under study. 
3. Some potential risk and protective factors de-
serve more attention. For example, the role of 
pregnancy and childbirth in the development of 
UI, AI and POP must be studied in a fashion that 
links population-based methods to clinical as-
sessment of pregnancy, delivery and birth 
trauma and follows women over many years. 
Such a design is necessary because the effect of 
pregnancy and childbirth may become clear only 
years later when the woman is older and be-
cause the woman will not then be able to report 
the exact nature of the tear, episiotomy, etc. 
4. There should be more emphasis on the associa-
tions between UI, AI and POP and specific dis-
eases like stroke, diabetes, and psychiatric dis-
eases. 
5. The variation of disease occurrence in groups of 
different racial origin yet similar environmental 
exposures, lend support to the presumed genetic 
influence on the causation of UI, AI and POP. 
This again provides circumstantial evidence for a 
genetic contribution to pelvic floor muscle disor-
ders since most of these studies have been una-
ble to control for heritability in relation to the com-
plex interaction of environmental factors. 
The aetiology of UI, AI and POP is widely recog-
nised to be multifactorial, yet the complex inter-
action between genetic predisposition and envi-
ronmental influences is poorly understood. Ge-
netic components require further investigation. 
Twin studies provide a possible means of study-
ing the relative importance of genetic predisposi-
tion and environmental factors. By comparing 
monozygotic female twins with identical geno-
type, and dizogytic female twins who, on aver-
age, share 50 percent of their segregating 
genes, the relative proportions of phenotypic var-
iance resulting from genetic and environmental 
factors can be estimated. A genetic influence is 
suggested if monzygotic twins are more concord-
ant for the disease than dizygotic twins whereas 
evidence for environmental effects comes from 
monozygotic twins who are discordant for the 
disease. 
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5. RECOMMENDATIONS FOR 
FURTHER BASIC SCIENCE 
RESEARCH 
The following proposals for research come from the 
Committees’ work in reviewing the current literature 
on Basic Science: 
1. Integrate data from reductionist experiments to 
inform the formulation of better systems-based 
approaches in the investigation of the pathology 
of the lower urinary tract (LUT), the genital tract 
(GT) and the lower gastro-intestinal tract (LGIT). 
2. Encourage greater emphasis on basic research 
to characterise tissues receiving relatively little 
attention: ie the lower gastrointestinal tract; the 
bladder neck and urethra; the ureter, pelvic floor 
musculature.  
3. Generate research programmes for fetal and ne-
onatal research in LUT and LGIT function. 
4. Use genome-wide bioinformatic and population 
health surveys to generate testable hypotheses 
regarding the physiological and pathophysiologi-
cal functions of the LUT, GT and LGIT. 
5. Generate improved experimental approaches to 
investigate the pathophysiology of the LUT and 
LGIT by: 
o The development of animal models that ac-
curately describe human pathological condi-
tions, including the greater use of large-ani-
mal models 
o The better use of reverse translational ap-
proaches for linking animal models to the 
human disease. 
o The use of human tissue from well-charac-
terised patient groups. 
o The development of emerging areas such 
as: tissue engineering; proteomics and 
metabolomics 
o Increased collaborations between biologi-
cal, physical and mathematical sciences. 
6. Develop centres of excellence or consortia of ex-
cellence in LUT, GT and GIT research 
o Integrate expertise from university depart-
ments, academic medical units and industry 
o Encourage translational approaches to re-
search.  
o Develop inter-institutional research-training 
programmes to allow new researchers the 
opportunity to better interact and exchange 
ideas. 
7. Bring about a greater emphasis on the im-
portance of research to medical trainees and sci-
ence graduates through: 
o Establishing research training as a core 
component of postgraduate clinical develop-
ment 
o Increased access to support funds, espe-
cially scholarships and personal awards 
o Organisation of focused multidisciplinary re-
search meetings, either stand-alone or as 
dedicated sessions during national and in-
ternational conferences 
o Greater interaction between medical centres 
and Higher Education Institutions (HEIs). 
o Allowing researchers-in-training better ac-
cess to international meetings through re-
duced registration charges and improved 
travel grants. 
o Inclusion in clinical meetings of point-coun-
terpoint session(s) with both basic science 
and clinical viewpoints. 
o Development of research forums for ex-
change of ideas between active researchers 
and industry. 
o Lobbying research-funding organisations 
about the medical and social importance of 
LUT and LGIT disorders. 
8. Increase emphasis on research into LUT and 
LGIT in HEIs through: 
o Greater representation on grant-funding 
agencies 
o Encouragement of submission to high im-
pact factor journals and recognition of re-
search published in specialty journals 
o More integrated teaching and training op-
portunities 
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6. RECOMMENDATIONS FOR 
PRIMARY PREVENTION, 
CONTINENCE PROMOTION, 
MODELS OF CARE AND 
EDUCATION 
Primary prevention, continence promotion and advo-
cacy, models of care and education involves inform-
ing and educating the public and health care profes-
sionals that UI and FI are not inevitable, but are treat-
able or at least manageable. Other bladder disorders 
such as BPS/IC and POP can also be treated suc-
cessfully. The committee found information about re-
cent practice and research initiatives in all of these 
areas but evidence-based research only on primary 
prevention of UI.  Continence promotion and advo-
cacy, and professional and non-professional educa-
tion, require prioritisation by public health profession-
als, educationalists, clinicians and researchers to re-
duce the burden that UI, FI, BPS/IC and POP places 
on society, healthcare systems, caregivers, and 
above all, affected adults.  As to models of care, the 
evidence supports nurse-led community services as 
leading to higher health-related QoL and in some in-
stances, higher cure rates. The multidisciplinary re-
ferral settings are also reporting favourable out-
comes. 
1. PRIMARY PREVENTION 
• Pelvic floor muscle exercises can prevent UI in 
pregnant and postpartum women. (Level of Evi-
dence: 1) 
• Education designed for community-dwelling 
older women can prevent UI. (Level of Evidence: 
1) 
• No recent RCTs or case-control studies were lo-
cated for prevention of FI. (Level of Evidence: 4) 
• Pelvic floor muscle exercises should be provided 
for pregnant women. (GoR A) 
• Education of older women to prevent UI should 
be provided. (GoR A) 
• Continence promotion is required to address 
broad gaps in knowledge about incontinence 
(GoR C) 
• Strategies to promote awareness about inconti-
nence and its treatment can be strengthened by 
the use of evidence based theories and methods 
from the field of health promotion, including the 
social determinants of health (GoR D) 
• The Internet represents an important source of 
information about incontinence, however the 
quality of information is variable (GoR C) 
• For help-seeking behaviour, no RCTs or case-
control studies were located (Level of Evidence 
4) 
• Continence promotion programmes need to ac-
commodate varying levels of health literacy and 
access to health information in different popula-
tions (Level of Evidence: 4) 
• Public health campaigns about incontinence and 
other pelvic floor disorders need to use terminol-
ogy targeted to consumers’ understandings 
(Level of Evidence: 4) 
• Satisfaction surveys about continence care could 
yield relevant and detailed information by using 
open-ended, rather than closed-ended questions 
(Level of Evidence: 1) 
• Evidence for the use of leaflets or brochures in 
raising awareness about UI and different treat-
ment options is inconclusive (Level of Evidence: 
1). 
• Evidence for the impact of continence advocacy 
worldwide was based on opinion (Level of Evi-
dence: 1) 
• Recommendation for help-seeking behaviour: 
No recommendation was possible based on the 
level of evidence provided by the available re-
search. 
• Worldwide Advocacy (GoR D) 
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2. MODELS OF CARE 
• Effectiveness of service delivery models. (Level 
of Evidence: 4) 
• A care delivery model should be based on the 
principles as described in the Optimum Conti-
nence Service Specification. (GoR C)  
• Increased emphasis is needed on non-physician 
models of care. (GoR C) 
• Despite the proliferation of guidelines, there is in-
creasing evidence that practicing clinicians and 
nurses are not consistently following them.  Im-
plementation models should be developed on 
how to translate guidelines into practice. (GoR C) 
3. EDUCATION 
• Professional education of UI, FI, BPS/IC, and 
POP is not evident as determined by materials 
reviewed.  (Levels of Evidence: 3-4) 
• Effectiveness of guidelines in clinical practice 
has not been determined. (Levels of evidence: 3 
to 4). 
• There is a continued need for evaluation re-
search to explore impact of guidelines on clinical 
care both at individual and population levels.  
This evaluation strategy needs to include impact 
on a wide range of outcomes, including inci-
dence and prevalence of disease, treatment out-
comes, prevention efforts, costs, and health care 
policy. (GoR: C) 
• Effectiveness of public education efforts through 
various channels including education, public me-
dia and mass communications (Levels of Evi-
dence 3-4) 
• There is a need for additional focused research 
on methods to enhance patient and public about 
pelvic disorders, both at an individual and 
broader public level. (GoR C) 
• The role of technology in public education for 
continence promotion should be examined in 
more depth. (GoR C) 
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7. RECOMMENDATIONS FOR 
TRANSLATIONAL AND CLINICAL 
RESEARCH 
A. RECOMMENDATIONS ON 
STUDY CONDUCT AND 
STATISTICAL METHODS 
The role of quality RCTs as providing the strongest 
level of evidence in incontinence research should be 
fully acknowledged by researchers, journal review-
ers, and editors. (GoR  A) 
Careful attention to the planning and design of all re-
search, especially RCTs, is of the utmost importance. 
(GoR A) 
Appropriate expertise in biostatistics and clinical trial 
design should be employed at the design phase of a 
RCT and thereafter on an ongoing basis. For Phase 
4, phase 5, and implementation trials, health eono-
mists should be included in trial design to support 
questions of value (cost-effectiveness).  (GoR  A) 
The design, conduct, analysis and presentation of 
RCTs must be fully in accordance with the 
CONSORT Statement. (GoR  A) 
The design, conduct, analysis and presentation of ob-
servational studies should follow STROBE guide-
lines. (GoR A) 
The design, conduct, analysis and presentation of 
meta-analyses should follow QUORUM guidelines. 
(GoR  A) 
Reporting studies of diagnostic tests, including urody-
namics, should follow the STARD statement guide-
lines. (GoR  A) 
B. RECOMMENDATIONS ON 
RESEARCH CONDUCT 
1. RECOMMENDATIONS FOR 
CONSERVATIVE TREATMENT 
TRIALS 
Use correct terminology to describe the intervention. 
(GoR  A) 
Report details of ability to perform correct contraction, 
dose-response issues and adherence. (GoR  A) 
Use recommended outcome measures with high re-
sponsiveness, reliability and validity. (GoR  A) 
Compare new methods with the best available inter-
vention. (GoR  A) 
Use power calculation in planning of the study. Avoid 
large sample sizes and weak (ineffective dosages) in-
terventions. (GoR  A) 
For long-term follow-up studies report cross-over, co- 
interventions, recurrent and competing events, ad-
herence in the follow-up period and loss to follow- up. 
(GoR  A) 
2. RECOMMENDATIONS FOR 
SURGICAL AND DEVICE TRIALS 
• The safety and serious side effects of new oper-
ations must be completely defined with adequate 
follow-up so that risks can be weighed against 
efficacy. At a minimum, this requires more use of 
large scale, independent, prospective, multicen-
tre cohort studies when RCTs are not practical. 
(GoR A) 
• Safety and serious side effects of incontinence 
devices must be completely defined with ade-
quate follow-up, especially for use of implantable 
devices and biological materials, so that risks 
can be weighed against efficacy. (GoR A) 
• Valid informed research consent is required in all 
trials of surgical interventions, which is separate 
from the consent for surgery. (GoR  A) 
• We recommend ongoing research into the use-
fulness of pre- and post-operative predictive test-
ing (such as urodynamics, ultrasound, MRI, etc) 
in surgical trials. (GoR  A) 
• Reports of successful treatment should be lim-
ited to subjects with a minimum (not mean) of 
one-year follow-up and should include a patient 
perspective measure. Specific assumptions 
about subjects lost to follow-up should be stated. 
(GoR A) 
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• Randomisation for surgical trials should occur at 
the time of surgery to minimise drop-outs and 
switch of procedure (GoR A) 
• Long-term follow-up of RCT cohorts in an obser-
vational cohort is recommended (GoR A) 
3. RECOMMENDATIONS ON COST 
ANALYSIS IN INCONTINENCE 
• Cost analysis should be incorporated into clinical 
studies whenever possible (137). (GoR A) 
• Cost analysis should describe the perspective of 
the analysis and analyses using the societal per-
spective and the payer perspective are useful.  
(GoR A)  
C. RECOMMENDATIONS FOR 
SPECIFIC PATIENT GROUPS 
1. MEN AND WOMEN WITH LUTS 
1.1. Men with LUTS 
• Measurement of prostate size should be per-
formed before and after treatment (at the same 
time as continence outcome measures where 
possible) whenever prostate size is considered 
to be a variable, or to change during the interven-
tion and follow up. (GoR A) 
• Maximum free flow rate and measurement of 
post- void residual urine should be recorded pre- 
treatment and the effect of therapy on these pa-
rameters should be documented simultaneously 
with assessment of the primary outcome varia-
bles. (GoR A) 
• Participants should be stratified by prostate size 
at randomisation when size is considered to be a 
potentially important determinant of treatment 
outcome. (GoR C) 
1.2. Women with LUTS 
• Specific information about menopausal status, 
hysterectomy, parity/obstetric history, and hor-
monal status should be included in baseline clin-
ical trial data and controlled for in specified anal-
yses in the research protocol. (GoR A) 
• High quality, symptom and bother scores 
(e.g.,ICIQ-FLUTS, ICIQ-SF, ICIQ-QoL(KHQ) , 
PISQ, ICIQ- FLUTSsex) validated in women 
should be employed when assessing outcomes. 
(GoR A) 
• Standardised assessment of pelvic organ pro-
lapse should be performed before treatment and 
at the time of other outcome assessments in all 
research where prolapse and continence out-
comes are being assessed. (GoR A) 
• Criteria for cure/improvement/failure from incon-
tinence treatment should be defined in the proto-
col based on patient perception as well as objec-
tive and semi-objective instruments such as val-
idated questionnaires, diaries and pad tests. 
(GoR A) 
• Assessment of the impact of treatment on sexual 
function should be performed with other outcome 
assessment when appropriate. (GoR B) 
2. CHILDREN 
• Long-term follow-up is of critical importance in 
the paediatric population in order to ascertain the 
effect of a treatment on normal growth and de-
velopment. (GoR A) 
• Research is needed to develop standardised 
outcome measures including validated, age- 
specific symptom and disease-specific quality of 
life outcome measures. (GoR B) 
3. NEUROGENIC POPULATIONS 
• Detailed urodynamic studies are recommended 
for classification of neurogenic lower urinary    
tract disorders in research studies because the 
nature of the lower tract dysfunction cannot be 
accurately predicted from clinical data. Videouro-
dynamic studies are preferred but are not man-
datory. (GoR C) 
• An area of high priority for research is the devel-
opment of a classification system to define neu-
rogenic disorders. Relevant features could in-
clude the underlying diagnosis, the symptoms, a 
precise documentation of the neuromuscular le-
sion by clinical neurophysiologic testing, and the 
nature of the urodynamic abnormality. (GoR C) 
4. POPULATIONS AFFECTED BY 
BLADDER PAIN SYNDROME 
(INCLUDING INTERSTITIAL 
CYSTITIS) 
• Broader entry criteria should be used to reflect 
the full spectrum of the BPS/IC patient popula-
tion. (GoR B) 
• The primary endpoint of BPS/IC trials should be 
patient driven and the Global Response Assess-
ment is recommended. A wide spectrum of sec-
ondary endpoints will be useful in defining the ef-
fect of treatments. (GoR  B) 
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5. POPULATIONS AFFECTED BY 
PELVIC ORGAN PROLAPSE 
• A validated standardised assessment of pro-
lapse (eg POP-Q) should be used for baseline 
and outcome assessments. (GoR A) 
• Complete reporting of outcomes including a vali-
dated assessment of anatomy, functional status, 
and complications is essential. (GoR A) 
• Complications/adverse events (especially for 
mesh) must be explicitly and completely reported 
in any research. (GoR A) 
• Long term outcomes (> 2 years) of intervention 
studies are needed. (GoR A) 
D. RECOMMENDATIONS FOR 
ETHICS IN RESEARCH 
The GoR for this section is A. 
Continuity in clinical direction from design through au-
thorship is mandatory. Investigators should be in-
volved in the planning stage and a publications com-
mittee should be named at the beginning of the clini-
cal trial. The Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals, from the Interna-
tional Committee of Medical Journal Editors should 
be followed. Authorship requires: 
• Substantial contributions to conception and de-
sign or acquisition of data or analysis and inter-
pretation of data, 
o Drafting the article or revising it critically for 
important intellectual content, 
o Final approval of the version to be published 
• Authors should provide a description of what 
each contributed and editors should publish that 
information. 
• Authors should have access to all raw data from 
clinical trials, not simply selected tables 
Clinical trial results should be published regardless of 
outcome. The sponsor should have the right to review 
manuscripts for a limited period of time prior to publi-
cation but the manuscript is the intellectual property 
of its authors, not the sponsor. 
• All authors should be able to accept responsibil-
ity for the published work and all potential con-
flicts of interest should be fully disclosed 
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8. INTERNATIONAL 
CONSULTATION ON 
INCONTINENCE MODULAR 
QUESTIONNAIRE (ICIQ): 
QUESTIONNAIRES AND 
BLADDER DIARY 
A. INTERNATIONAL 
CONSULTATION ON 
INCONTINENCE MODULAR 
QUESTIONNAIRE (ICIQ) 
The scientific committee which met at the end of the 
1st ICI in 1998 supported the idea that a universally 
applicable questionnaire should be developed, that 
could be widely applied both in clinical practice and 
research and should reflect the patients’ perspective 
of their situation.  
The hope was expressed that such a questionnaire 
would be used in different settings and studies and 
would allow cross-comparisons, for example, be-
tween a drug and an operation used for the same 
condition, in the same way that the IPSS (Interna-
tional Prostate Symptoms Score) has been used.  
An ICIQ Advisory Board was formed to steer the de-
velopment of the ICIQ and met for the first time in 
1999. The project’s early progress was discussed 
with the Board and a decision made to extend the 
concept further and to develop the ICIQ Modular 
Questionnaire to include assessment of urinary, 
bowel and vaginal symptoms(1). The first module to 
be developed was the ICIQ Short Form Question-
naire for urinary incontinence: the ICIQ-UI Short Form 
(2) (Fig 1). The ICIQ-UI Short Form is now widely 
used globally and since 2004 its use or further devel-
opment has been reported in almost 100 publications. 
Given the intention to produce an internationally ap-
plicable questionnaire, requests were made for trans-
lations of the ICIQ-UI Short Form at an early stage, 
for which the Advisory Board developed a protocol for 
the production of translations of its modules. The ICIQ 
modules have been translated into over 40 languages 
to date across the various modules.  
Since the fifth consultation a further two modules 
have been published and are available for use: the 
ICIQ Bladder Diary (3,4) and ICIQ-LTCqol(5). The 
bladder diary is the first fully validated bladder diary, 
which notably incorporated patient and clinician input 
during its development. The ICIQ-LTCqol question-
naire provides an assessment of symptoms, impact 
and bother associated with indwelling catheter use. 
This brings the total number of available modules to 
sixteen. 
With increasing demand for electronic versions of 
questionnaires, a study has been conducted by the 
ICIQ group to evaluate the equivalence of the ICIQ’s 
psychometric properties in alternative formats (6). 
With equivalence demonstrated, app development for 
the eICIQ is underway. 
www.ICIQ.net provides details of the validation status 
of the modules under development for urinary symp-
toms, bowel symptoms and vaginal symptoms and 
provides information regarding the content of existing 
modules. Information regarding production of transla-
tions and the ICIQ development protocol is also avail-
able for those interested in potential collaborations to 
continue development of the project. 
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Figure 1: ICIQ-UI Short Form
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B. ANNEX 1 BLADDER CHARTS 
AND DIARIES 
The ICS defines three types of Bladder Charts and 
Diaries which can be used to collect data: 
MICTURITION TIME CHART 
• times of voiding and 
• incontinence episodes 
FREQUENCY VOLUME CHART 
• times of voiding with voided volumes measured, 
• incontinence episodes and number of changes 
of incontinence pads or clothing 
. 
BLADDER DIARIES 
• the information above, but also 
• assessments of urgency, 
• degree of leakage (slight, moderate or large) and 
descriptions of factors leading to symptoms such 
as stress leakage, eg. running to catch a bus. It 
is important to assess the individual’s fluid in-
take, remembering that fluid intake includes flu-
ids drunk plus the water content of foods eaten. 
It is often necessary to explain to a patient with 
LUTS that it may be important to change the tim-
ing of a meal and the type of food eaten, particu-
larly in the evenings, in order to avoid trouble-
some nocturia. 
The recent development and publication of the ICIQ 
Bladder Diary provides the first fully validated bladder 
diary that incorporated patient, clinician and statistical 
Table 1: Fully validated ICIQ modules and derivation 
MODULES AVAILABLE FOR USE 
ICIQ-MLUTS(7) 
(ICSmale Short Form) 
Urinary symptoms (male) 
 
ICIQ-FLUTS(8) 
(BFLUTS Short Form) 
Urinary symptoms (female) 
ICIQ-VS(9) Vaginal symptoms and quality of life 
ICIQ-B(10,11) Bowel symptoms and quality of life 
ICIQ-UI Short Form(2) Urinary incontinence short form 
ICIQ Bladder diary(3,4) Bladder events and fluid intake 
ICIQ-N(12,13) 
(ICSmale/BFLUTS) 
Nocturia symptoms 
ICIQ-OAB(12,13) 
(ICSmale/BFLUTS) 
Overactive bladder symptoms 
ICIQ-MLUTS Long Form(12) 
(ICSmale) 
Urinary symptoms long form (male) 
ICIQ-FLUTS Long Form(13) 
(BFLUTS) 
Urinary symptoms long form (female) 
ICIQ-LUTSqol(14) 
(KHQ) 
Urinary symptoms quality of life 
 
ICIQ-Nqol(15) 
(N-QoL) 
Nocturia quality of life 
ICIQ-OABqol(16) 
(OABq) 
Overactive bladder quality of life 
ICIQ-LTCqol(5) Long term catheter symptoms and quality of life 
ICIQ-MLUTSsex(12) 
(ICSmale) 
Sexual matters related to urinary symptoms (male) 
ICIQ-FLUTSsex(13) 
(BFLUTS) 
Sexual matters related to urinary symptoms (female) 
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input during its development (3,4). This rigorous de-
velopment methodology has ensured the provision of 
a psychometrically robust tool that reflects the key is-
sues from a patient’s and clinical perspective to ena-
ble the gathering of required information to treat pa-
tients with LUTS (Fig 1). The diary is intended to be a 
standalone tool that provides instructions and an ex-
ample to guide completion. The diary is intended for 
completion over three days and fits onto two sides of 
A4 to optimise administration and completion. Data 
collected are: 
• Fluid intake 
• Urine output 
• Leakage episodes 
• Time of sleep and waking 
• Pads used 
• Optional bladder sensation scale 
The bladder sensation scale is intended to be an in-
terchangeable variable that can be replaced with a 
more pertinent measure for an intended use, for ex-
ample, a pain scale. It is advised that any scale used 
in this manner should  be validated. 
INSTRUCTIONS FOR USING THE BLADDER 
DIARY 
This diary helps you and us to understand why you 
get trouble with your bladder. The diary is a very im-
portant part of the tests we do, so that we can try to 
improve you symptoms. On the chart you need to rec-
ord: 
9. When you get out of bed in the morning, show 
this on the diary by writing ‘GOT OUT OF BED’. 
10. During the day please enter at the correct time 
the drinks you have during the day, eg. 8.00am 
– two cups of coffee (total 400 ml). 
11. The time you pass your urine, eg. 7.30am. Do 
this every time you pass urine throughout the day 
and night. 
12. Each time you pass urine, collect the urine in a 
measuring jug and record the amount (in mls or 
fluid ozs) next to the time you passed the urine, 
eg. 1.30pm/320ml. 
13. Each time you pass your urine, please write 
down how urgent was the need to pass urine: 
‘O’ means it was not urgent. 
+ means I had to go within 10 minutes. 
++ means I had to stop what I was doing and go 
to the toilet. 
14. If you leak urine, show this by writing an ‘W’ on 
the diary at the time you leaked. 
15. If you have a leak, please add ‘P’ if you have to 
change a pad and ‘C’ if you have to change your 
underclothes or even outer clothes. So if you leak 
and need to change a pad, please write ‘WP’ at 
the time you leaked. 
16. If you have a leakage please write in the column 
called ‘Comments’ whether you leaked a small 
amount or a large amount and what you were do-
ing when you leaked, eg. ‘leaked small amount 
when I sneezed three times’. 
17. Each time you change a pad or change clothes, 
please write in the ‘Comments’ column. 
18. When you go to bed at the end of the day show 
it on the diary - write ‘Went to Bed’. 
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Figure 2: ICIQ-Bladder Diary (page 1) 
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Figure 3: ICIQ-Bladder Diary (page 2) 
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